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Preamble
It is becoming more apparent each day that despite a strong
national commitment to excellence in health care, the re-
sources and personnel are finite . It is, therefore, appropriate
that the medical profession examine the impact of develop-
ing technology on the practice and cost of medical care .
Such analysis, carefully conducted, could potentially have
an impact on the cost of medical care without diminishing
the effectiveness of that care .
Add- for
r
epdnis : Michael Foncinito
. Special Projects, American
College of Cardiology . 9111 Old Georgetown Road, Bethesda, Maryland
20914.
Gaidelinesfor the Early Management of Patients With Acute Myocardial
Inleravn were approved by the American College of Cardiology Board of
Trustees on Match 17, 1990and by the American Heats Association Staring
Committee on February 21, 1990 .
01990
by the Aeteticao College of Camialogy
ROLF M, GUNNAR, MD, FACC, Chai-aut
PATRICK D . V. BOURDILLON . M D. FACC
DONALD W. DIXON . MD. FACC
VALENTIN FOSTER, MD, FACC
ROBERT B . KARP . MD, FACC
J . WARD KENNEDY, MD. FACC
FRANCIS J . KLOCKE, MD, FACC
TASK FORCE MEMBERS
CHARLES FISCH . M D. FACC. Chairman
GEORGE
A. BELLER . M D. FACC
ROMAN W
. DESANCTIS, MD
. FACC
HAROLDT. DODGE. MD . FACC
J. WARD KENNEDY, MD. FACC
T. JOSEPH REEVES. MD, FACC
SYLVAN LEE WEINBERG, MD, FACC
EUGENE R- PASSAMANI, MD. FACC
BERTRAM PITT,
MD, FACC
ELLIOT RAPAPORT
. MD .
FACC
T. JOSEPH REEVES, MD, FACC
RICHARD O. RUSSELL, JR ., MD, FACC
BURTON E . SOBEL . M D. FACC
WILLIAM L
. WINTERS, JR ., MD, FACC
249
To this end, the American College of Cardiology and the
American Heart Association in 1980 established a Task
Force on Assessment of Diagnostic and Therapeutic Cardio-
vascular Procedures with the following charge :
The Task Force of the American College of Cardiology and
the American Heart Association shall define the role of
specific noninvasive and invasive procedures in the diag-
nosis and management of cardiovascular disease .
The Task
Fore,:
shall address, when ap oopriale, the contri-
bution, uniqueness, sensitivity, specificity . indications,
contraindications and cosbelfectiveness of such specific
procedures.
The Task Force shall include a Chairman and six members,
three representatives from the American Heart Associa-
tion and three representatives from the American College
of Cardiology . The Task Farce may select ad hoc mem-
hers as needed upon the approval of the Presidents ofbo(h
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organizations. Recommendations of the Task Force are
forwarded to the President of each organization.
The members of the Task Force are
: George A . Beller,
MD, Roman W
. DeSanctis, MD, Harold T
. Dodge
. MD, J
.
Ward Kennedy, MD, T . Joseph Reeves, MD, Sylvan Lee
Weinberg, MD and Charles Fisch, MD, Chairman.
This document was reviewed by the officers and other
responsible individuals of the two organizations and re-
ceived final approval in March 1990. It is being published
simultaneously in Circulation and the Journal of the Amer-
ican College of Cardiology. The potential impact of this
document on the practice of cardiology and some of its
unavoidable shortcomings are clearly set out in the introduc-
tion.
Charles Fisch, MD, FACC
Introduction to Acute Myocardial Infarction
Coronary artery disease is the leading cause of death in
the United States . Despite an encouraging 47% reduction in
age-adjusted coronary mortality rates over the past 25 years,
coronary disease caused 514,000 deaths in 1987 (1) . There
were approximately 750,000 patients admitted to hospitals
with acute myocardial infarction during 1987 in the United
States (2). There are roughly 7 million patients with diag-
nosed coronary disease in this country and many more with
clinically silent coronary atherosclerosis. Morbidity and
mortality in pate .ts with coronary artery disease in general,
and in heart attack victims in particular, are in large part
determined by the extent of heart muscle damage as well as
the number and severity of coronary atherosclerotic lesions .
Developments in treatment of myocardial infarction .
From the time the myocardial infarction syndrome was first
related to coronary thrombosis in 1912 through the 1940s,
treatment progressed slowly, with no landmark changes
except, perhaps, the introduction of oral anticoagulant ther-
apy . There were interminable debates about digitalis usage
and the length of absolute bed rest needed in the treatment of
such patients. In the late 1950s, coronary care units were
developed
. With development of direct current defibrillators
and closed chest cardiopulmonary resuscitation in the 1960s,
a significant impact was made on the early mortality rate of
myocardial infarction. The 1960s also saw the development
of hemodynamic monitoring of patients with myocardial
infarction and recognition of hypovolemia as a correctable
cause of shock in a percentage of such patients . Finally, the
development of counterpulsation improved survival in the
patients with pump failure, but only to a minimal extent . The
1970s witnessed more universal training of medical and
nonmedical personnel in cardiopulmonary resuscitation and
deployment of mobile coronary care units (first developed by
Pantridge and Geddes in 1967 [3]). The 1970s saw use of
pharmacologic methods for myocardial preservation by im-
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provement of nutrient supply to the myocardium through
interstitial diffusion using hyaluronidase or glucose-insulin-
potassium solution and decrease in myocardial oxygen re-
quirements with use of beta-adrenergic blockers and unload-
ing agents.
Physicians in Spokane, Washington made the next major
leap forward by providing reperfusion through early coro-
nary artery bypass surgery (4) . DeWood et al. (5) presented
convincing evidence that there was thrombosis of the coro-
nary artery early in myocardial infarction and this thrombus
likely had spontaneous lysis over the ensuing hours in some
patients. The surgical experiences in Spokane and later in
Iowa (6) were outstanding tours de force in reperfusion by
surgical thrombectomy and coronary bypass, but did not
lead to universal application because of logistic impractical-
ity.
In 1976, Chazov et al. (7) reported on intracoronary
fibrinolysis in acute myocardial infarction . Rentrop et al . (8)
used catheter-directed reperfusion by mechanically opening
the artery and then using intracoronary thrombolytic agents .
As time went on, it became clear that the delay while waiting
for intracoronary thrombolytic agents was using up the time
window for best myocardial salvage by reperfusion. Thus,
the Gruppo Italian per to Studio delta Streptochinasi
nell'Infarto Miocardico (GISSI) trial (9), the first large scale
study of early intravenous thrombolysis, is the milestone
that marks the beginning of the era of routine thrombolysis in
patients with early acute myocardial infarction . The devel-
opment of the second generation thrombolytic agents that
are more clot-specific may well improve the safety and
efficacy of thrombolysis. The third generation, which may be
represented by single chain pro-urokinase, could further
improve safety and efficacy: however, despite hope for
further improvements, there is little doubt that patients who
receive thrombolytic reperfusion early in acute myocardial
infarction and are not excluded from thrombolytic therapy
by specific contraindicators show significantly improved
survival (9-12) and ventricular function (13).
Current guidelines for treatment . In this review, it is
incumbent to establish as best we can current guidelines for
treatment of acute myocardial infarction, including the cur-
rent use of thrombolytic agents. We recognize that we are
shooting at a moving target, but enough has been established
that we think guidelines can be developed appropriately and
must be developed at this time . These guidelines should not
be considered rigid; rather they are guides to be modified by
clinical judgment and individual patient needs. The next
major step may well be newer methods of preserving or
preventing further destruction of the myocardium after tem-
porary occlusion using such agents as oxygen-free radical
scavengers. However, these interventions are still in the
discovery phase and are not appropriate for ourguidelines at
this time.
Throughout this report, we have used the following
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classification of indications for diagnostic procedures and
therapeutic interventions:
Class I = usually indicated, always acceptable and
considered useful/effective .
Class 11 = acceptable, of uncertain efficacy and may be
controversial.
a = weight of evidence in favor of useful-
ness/efficacy .
b = not well established by evidence, can be
helpful and probably not harmful .
Class Ill = not indicated, may be harmful .
Rein of patient education to early treatment . Patients with
acute myocardial infarction can receive optimal medical
management only when they seek medical care early in the
course of the illness. Many current strategies for care,
including thrombolytic therapy, are most effective when
started early in the course of infarction . Treatment for
life-threatening complications of infarction, including ven-
tricular fibrillation and cardiogenic shock, is, of course,
available only to patients who are under medical observation
when these events occur
. Because of the extreme impor-
tance of early medical care in the treatment of acute myo-
cardial infarction, the portion of the adult population at risk
of having an acute infarction must be educated about the
symptoms of infarction and how to seek emergency cardiac
care in their community. It is the obligation of physicians
who care for patients with known coronary artery disease as
well as those receiving medical care for illnesses that in-
crease the risk of myocardial infarction (for example, diabe-
tes, hypertension and peripheral vasculardisease) to educate
their patients about the recognition of and response to
symptoms of infarction.
Emergency cue systems. Each community must take the
responsibility of developing a plan for the early management
and triage of patients with suspected acute myocardial
infarction . When possible, the emergency care system
should have a group of well trained emergency medical
technicians who have a physician-directed plan for the care
of these patients.
Evaluation of patients in the field should be carried out
with a specific protocol . Patients should be evaluated rapidly
and transferred to a nearby hospital equipped to manage
patients with acute myocardial infarction . Patients who are
critically ill, such as those who have had a cardiac arrest,
have repetitive episodes of ventricular tachyarhythmias or
severe bradycardia or are in shock, should be taken to a
hospital with cardiac catheterization and cardiac surgery
facilities instead of to a smaller community hospital without
such facilities if this will not require excessive transport
time
. Plans for the triage of critically ill patients to a tertiary
hospital should be part of every community plan.
GUNNAR ET AL
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Emergency departments must be able to rapidly assess
patients with suspected myocardial infarction
. The emer-
gency department must make every effortto identify patients
with suspected acute myocardial infarction when they enter
the department . Patients with chest pain, chest tightness,
acute epigastric distress and other symptoms suggestive of
acute myocardial infarction must be evaluated quickly and,
when appropriate, placed on a protocol
. These patients
should have electrocardiographic (ECG) monitoring from
the time of entry, an immediate Nit ECG, frequent vital signs
and be seen by a physician within the first few minutes of
arrival in the emergency department. Delays in evaluation
and treatment related to hospital administrative procedures,
such as establishing insurance coverage, must not be al-
lowed to occur.
In patients in whom the clinical presentation and ECG are
characteristic (classic) of acute myocardial infarction, the
initial therapy, including appropriate use of thrombolytic
therapy, should be begun by the appropriately trained emer-
gency department physician and staff . When the diagnosis of
acute myocardial infarction is less certain, consultation with
an immediately available cardiologist or internist should be
obtained . Prolonged efforts to consult with the patient's
private physician are inappropriate if this is likely to result in
a significant delay in initiating specific therapy
.
In rural
communities, patients with acute myocardial
infarction will often receive theirinitial care in hospitals with
limited special facilities and without physicians with special
training in acute cardiac care . In this situation, plans should
be developed with nearby medical centers for rapid tele-
phone consultation and appropriate patient transfer to a
tertiary medical center
. In many circumstances, protocols
forthe initiation of thrombolytic therapy in the rural hospital
before transfer are appropriate and have been shown to be
safe and effective .
Other eomlieratfr . In this docament we only touch on
treatment of arrhythmias and do not discuss modification of
risk factors. This should not reflect the
ir lack of importance,
but rather a decision that they have been treated well
elsewhere and are outside the scope of this document .
0XY9_
Even with uncomplicated myocardial infarction, some
patients are modestly hypoxemic initially
. Although the
exact mechanism for this hypoxemia is uncertain and may be
complex, it is likely that ventilation-perfusion mismatch
plays a prominent role (14) . Patients with associated conges-
tive heart failure have more severe hypoxemia .
Supplemental oxygen should be provided at least in the
initial hours for all patients suspected of having acute
ischemic pain . Oxygen should not be withheld during trans-
portation to the hospital, even if there is evidence of chronic
252
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pulmonary disease
; however, lower flow rates may be pru-
dent in these patients
.
Patients with severe congestive heart failure, pulmonary
edema or a mechanical complication of acute myocardial
infarction may fail to correct significant hypoxemia with
supplemental oxygen alone. Endotrache r intubation and
mechanical ventilation are often required in such cases and
should not be unnecessarily delayed
(15) .
Nitroglycerin
For more than 100 years nitroglycerin has relieved the
pain of myocardial ischemia for patients suffering from
coronary artery disease
. This benefit is achieved by the
actions of nitroglycerin to dilate epicardial conductance
arteries, increase collateral blood flow to ischemic myocar-
dium and decrease left ventricular preload .
Initial use ofaitroglyceria. Patients presenting with ische-
mic pain should receive sublingual nitroglycerin unless the
initial systolic blood pressure is <90 mm Hg . Even if the
systolic blood pressure is <90 mm Hg, a single sublingual
nitroglycerin tablet may be tried in the hospital provided
there is evidence of ongoing ischemic pain and an intrave-
nous line has been inserted . Nitroglycerin should be avoided
in the presence of marked bradycardia or tachycardia,
especially if relative hypotension is present (16) . Careful and
frequent observation of vital signs is necessary for several
minutes after the initial dose .
Long-acting oral nitrate preparations should be avoided
in the management of early acute myocardial infarction.
Sublingual or transdermal nitroglycerin can be used, but
intravenous infusion of nitroglycerin allows for more precise
minute to minute control of this agent. Intravenous nitro-
glycerin can be successfully titrated by frequent measure-
ment of cuff blood pressure and heart rate . Although inva-
sive hemodynamic monitoring is not mandatory, it may be
preferable if high doses of vasodilating agents are required,
blood pressure instability ensues or there is clinical doubt
about the adequacy of the left ventricular filling pressure
(17).
Preventing adverse effects. Nitroglycerin frequently
causes headache . It also may aggravate hypoxemia by
increasing ventilation-perfusion mismatch . Unquestionably,
however, inadvertent systemic hypotension with resulting
worsening of myocardial ischemia is the most serious poten-
tial complication of nitroglycerin therapy in patients with
acute myocardial infarction (I9) . Nitroglycerin should be
carefully titrated in patients with inferior wall myocardial
infarction and used with extreme caution, if at all, in patients
with suspected right ventricular infarction . Such patients are
especially dependent on adequate right ventricular preload
to maintain cardiac output and can experience profound
hypotension during nitrate administration
. If nitroglycerin
administration results in excessive bradycardia and hypoten-
JACC Vol. 16. Na . 2
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sion, discontinuation of the drug, leg elevation, rapid fluid
administration and atropine are appropriate therapies .
Effect of intravenous nitroglycerin on Infarct she and
mortality. There is experimental and clinical evidence (IS-
20) that intravenous nitroglycerin may reduce infarct size in
some patients. As with all interventions designed to salvage
myocardium, the best results occur when treatment begins
early, Nitroglycerin may decrease susceptibility to ventric-
ular fibrillation during both acute myocardial ischemia and
reperfusion (21). Meta-analysis of the pooled results of 10
studies seemed to demonstrate that intravenous nitrates also
reduce mortality by 10% to 30% (22) .
One recent randomized
trial (20) on intravenous nitroglycerin in 310 patients dem-
onstrated improved hospital survival (mortality rate 14%
versus 26%, p < 0.01) that was limited to patients with
anterior infarction. This benefit was sustained fort year (20) .
Despite these considerations, however, there are inadequate
data at present to recommend infusion of intravenous nitro-
glycerin in all patients with uncomplicated acute myocardial
infarction
.
Whatever its theoretic value in reducing infarct size and
mortality, however, intravenous nitroglycerin is of uncon-
tested value in suppressing ongoing myocardial ischemic
pain . Its benefit is also well established when acute myocar-
dial infarction is complicated by congestive heart failure or
pulmonary edema (17) .
Dosage
. When thrating intravenous nitroglycerin, begin
with a 15
J1g
bolus injection and a pump-controlled infusion
of 5 to 10 pglmin and increase the dosage by 5 to 10 pglmin
every 5 to 10 min while carefully monitoring hemodynamic
and clinical responses . Titration end points are the control of
clinical symptoms or a decrease in mean arterial pressure of
10% in normotensive patients or 30% in hypertensive pa-
tients (but never a systolic blood pressure <90 min Hg), an
increase in heart rate >10 beats/min (but not usually >110
beatsimin) or a decrease in pulmonary artery end-diastolic
pressure of 10% to 30%. Although there is no absolute upper
dosage limit, doses >200 jug/min are associated with an
increased risk of hypotension and alternative therapy should
be considered. Prolonged infusion may result in relative
nitrate tolerance . The combination of intravenous nitroglyc-
erin with a beta-adrenergic blacker in appropriate patients is
well tolerated and theoretically attractive because the risk of
undesireo tachycardia may be reduced. As tolerance devel-
ops, the infusion rate can be increased, but if it becomes
necessary to administer >200 pg/min, another vasodilator
such as a calcium channel blocker should be substituted with
the knowledge that effectiveness of nitroglycerin usually
returns after 12 h of removal from nitroglycerin .
Analgesia
The frequent clinical observation of rapid and complete
relief of pain after early reperfusion with thrombolytic that-
IACC Vor. 16, No. 2
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apy has made it clear that the pain of acute myocardial
infarction is due to continuing ischemia of living jeopardized
myocardium rather than to the effects of completed myocar-
dial necrosis . Efforts to control pain, therefore, may reason-
aLly involve utilization of anti-ischemic interventions includ-
ing, in addition to reperfusion, the use of oxygen, nitrates,
beta-adrenergic blocking agents and, under some circum-
stances, intraaortic balloon counterpulsation . Effective an-
algesia should be promptly administered at the time of
diagnosis, however, and not unreasonably delayed to eval-
uate the results of anti-ischemic therapy (17) .
Available agents
. The agents available to suppress the
pain of acute myocardial infarction include morphine sulfate,
hydromorphone and meperidine. Meperidine has been rec-
ommended for inferior wall infarction because of its
vagolytic properties. When equipotent analgesic doses are
given, however, it seems to have no clear advantage over
morphine (23) . Except in patients with documented hyper-
sensitivity to its use, morphine sulfate remains the drug of
choice to suppress the pain of myocardial infarction . It is
administered intravenously in small repeated doses of 2 to 5
mg every 5 to 30 min as needed . Relatively large cumulative
doses of 2 to 3 mglkg are occasionally required .
Morphine blocks sympathetic efferent discharge at a
central nervous system level, resulting in peripheral venous
and arterial dilation (24) .
As a consequence, there is a
reduction in both preload and aftertoad and a decrease in
myocardial oxygen demand. Pain is relieved and anxiety
decreased, leading to a decrease in circulating catechol-
amines and a possible reduction in associated arrhythmia
(23).
Side effects. Hypotension associated with inappropriate
bradycardia has been reported to occur rarely
. Leg eleva-
tion, fluids and atropine will correct the hemodynamic
status. Respiratory depression with aggravation of hypoxe-
miais a risk, especially in patients with chronic lung disease.
Respiratory depression is rarely encountered in the setting of
severe chest pain or pulmonary edema (23) . If it does occur,
its effects can be reversed with naloxone . although its
administration may reverse pain relief as well
.
Countershock
About 65% of deaths from recognizable acute myocardial
infarction occur in the first hour of the attack and most are
caused by ventricular fibrillation (25). If basic life support is
initiated by a bystander within 4 min and if defibrillation
occurs within 8 min of the cardiac arrest, 40% of patients will
live to be discharged from the hospital. When minimally
trained "first-responding rescuers" (such as police and
firefighters) were permitted to defibrillate ventricular fibril-
lation before paramedic arrival, marked improvement in
neurologic recovery was documented (26)
.
As many as 85%
GUNNAR ET AL,
	
253
ACCIAHA TASK FORCE REPORT
of episodes of ventricular fibrillation will be corrected by a
single shock of 2001.
An organized treatment protocol for the resuscitation of
patients with ventricular tachycardia and ventricular fibril-
lation has been established (27) and recently updated (28) .
Blind defibrillation in a pulseless patient may be attempted.
to a monitored setting with a defibrillator present, the
occurrence of witnessed ventricular fibrillation or pulseless
ventricular tachycardia should Lead to immediate nonsyn-
chronized defibrillation at 2001 without intervening basic life
support (28). If a pulse is not rapidly restored, subsequent
shocks at 20D to 3001 and again at 3601 should follow, It is
important to remember that ventricular fibrillation has a
"vector' and, depending on the ECG lead and the amplitude
of the fibrillatory waves, the ECG during ventricular fibril-
lation may appear to record ventricular asystole
. The diag-
nosis of "asystole," therefore, should always be confirmed
in at least two ECG leads or, if the distinction between fine
ventricular fibrillation and asystole is in doubt, delivery of a
countershock to the unconscious patient is appropriate (28),
Atropine
By its parasympathotytic (anticholinergic) activity, atro-
pine sulfate reduces vagal tone, enhances the rate of dis-
charge of the sinus node and facilitates atrioventricular (AV)
conduction (29) . It is frequently given as an adjunct to
morphine administration to reduce nausea and vomiting
.
During the early moments to hours of acute ischemia or
acute myocardial infarction, atropine is particularly useful in
treating sinus bradycardia with associated reduced cardiac
output and signs of peripheral hypoperfusion, including
arterial hypotension, confusion, faintness and grayish pallor
or frequent premature ventricular contractions (30) . In this
setting, leg elevation and the intravenous administration of
atropine may be lifesaving .
Atropine for AV block, shwa brady cardia
or valdlcab
W
Restate. Atropine is the drug of choice for the occasional
treatment of type I second degree AV block, especially when
complicating inferior myocardial infarction . It is rarely use-
ful in third degree AV block. When AV block or sinus
bradycardia is associated with congestive heart failure,
hypotension or frequent and complex ventricular arrhyth-
mias, atropine may improve AV conduction and increase the
sinus rate and may avert the need for immediate insertion of
a transvenous pacemaker (3p
. As a rule, however, in the
absence of hemodynamic compromise, treatment of sinus
bradycardia and AV block is not indicated . Similarly, atro
.
pine is rarely, if ever, the drug of choice for management of
type II second degree AV block . On occasion, while failing
to improve AV block, atropine may increase the sinus rate
and, in fact, enhance the block.
The recommended dosage of atropine for bradycardia is
0.5 mg intravenously, repeated if needed every 5 min to a
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total dose of no more than 2 mg, the amount that produces
complete vagal blockade . Atropine may also be therapeutic
in ventricular asystole, for which the recommended dose is I
mg intravenously, to be repeated in 5 min (while cardiopul-
monary resuscitation continues) if asystole persists . The
total cumulative dose should not exceed 2.5 mg over 2 .5 h .
The peak action of atropine given intravenously is observed
within 3 min.
Side effects
. Atropine in doses of <0.5 mg or when
administered other than intravenously may result in a para-
doxic effect (namely, bradycardia and depression of AV
conduction) (32) . The effects are due either to central reflex
stimulation of the vagus or to peripheral parasympathomi-
metic effect on the heart.
Repeated administration of atropine may produce ad-
verse central nervous system effects, including hallucina-
tions and fever. Careful observation is necessary after the
administration of atropine because the sinus tachycardia that
follows may increase ischemia . Rarely, ventricular tachycar-
dia and fibrillation occur after the intravenous administration
of atropine (33).
Pacemaker insertion is the treatment of choice for symp-
tomatic bradycardia not responding promptly to atropine
administration (see elsewhere) .
Recommendations for Atropine Use
The following indications are app,icable in the early
moments to 6 or 8 h after onset of acute myocardial
infarction .
Clam I
I
. Sinus bradycardia with evidence of low cardiac output
and peripheral hypoperfusion or frequent premature ven-
tricular contractions at the onset of symptoms of acute
myocardial infarction.
2. Acute inferior inf ration with symptomatic type I second
degree AV block.
3. Bradycardia and hypotension after nitroglycerin adminis-
tration .
4 . For nausea and vomiting associated with morphine ad-
ministration .
5
. Asystole
.
Class Iia
I . Administration concomitantly with (before or after) mor-
phiae administration in the presence of sinus bradycardia,
even without evidence of low cardiac output or peripheral
hypoperfusion .
2. Asymptomatic patients with inferior infarction and type I
second degree heart block or third degree heart block at
the level of the AV node (see Class 111-2)
.
Class III
1
. Sinus bradycardia >40 beats/min without signs or symp-
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Auauet 1990:2!9-92
toms of hypoperfusion or frequent premature ventricular
contractions.
2. AV block at the His-Purkinje level (that is, type II AV
block and third degree AV block with new wide QRS
complex).
Indications for Monitoring
Electrocarditgrttphic monitoring. Continuous ECG mon-
itoring must be established as rapidly as possible when a
patient with suspected acute myocardial infarction comes to
medical attention . Emergency medical technicians working
in the prehospital environment should be capable of estab-
lishing ECG monitoring as well as diagnosing and initiating
therapy for life-threatening arrhythmiss. Once ECG moni-
toring has been established, it should be continuous and
uninterrupted until the patient's condition has become stable
and the responsible medical staff have discharged the patient
from intensive cardiac care. In most patients, a single
anterior chest lead provides adequate ECG monitoring .
Recommendations for Electrocardiographic
Monitoring in Acute Myocardial Infarction
Class I
1 . Patients with acute myocardial infarction during the ini-
tial 48 to 72 h .
2 . Patients >72 h after acute myocardial infarction who
have hemodynamic instability, persistent ischemia or
arrhythmia.
3 . Patients with suspected myocardial infarction ("rule out"
myocardial infarction) during the initial 12 to 36 h
.
4 . Patients who have had insertion of a temporary trans-
venous pacemaker.
Chat 110
I
. Patients >72 h after acute myocardial infarction who
have a high likelihood of intermittent ischemia or com-
plex ventricular arrhythmias
.
2
. Patients with chest pain in whom there is a low likelihood
of myocardial infarction .
Class Hit
1 . Monitoring >72 It after myocardial infarction, particu-
larly if the patient has undergone thrombolysis or ang(o-
plasty .
Class in
I . Patients with or without known heart disease in whom
there is no evidence of myocardial ischemia, recent
infarction or arrhythmia .
Balloon flotation right heart
catheter
monitoring. The
balloon flotation catheter is of great value in the management
of patients with acute myocardial infarction who have an
unstable hemodynamic state, including low cardiac output,
hypotension, cardiogenic shock and pulmonary edema . This
JACC Vol . to No
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technique is most helpful when it identifies patients with
acute myocardial infarction who have low cardiac output
and hypotension due to low left ventricular filling pressures
.
The condition of patients often stabilizes rapidly with simple
fluid therapy (34). Unfortunately, the great majority of
patients with low cardiac output, hypotension or shock have
high left ventricular filling pressures and often are in pulmo-
nary edema . In these individuals, the balloon flotation cath-
eter can he used to monitor therapeutic efforts directed
toward adjusting the filling pressure so as to maximize
cardiac output at the lowest possible wedge pressure. These
sophisticated manipulations of the patient's hemodynamic
state would not be possible without readily available mea-
surements of right atrial, pulmonary artery and pulmonary
wedge pressures as well as frequent and convenient deter-
minations of cardiac output .
The balloon flotation catheter is a relatively safe device,
but nonetheless is associated with a low risk of serious
complications, including pulmonary hemorrhage or infarc-
tion. It also results in increased discomfort and immobiliza-
tion for the patient. There are many opportunities for the
pressure recorded from the tip of the balloon flotation
catheter to be distorted . These arlifactual pressures are most
readily identified when displayed with a strip chart recorder .
The coronary care unit monitoring equipment should, there-
fore, have the capacity to record as well as display the
pressure waveforms . Digital display of the pressure may be
inaccurate and misleading and cannot be relied on . A radio-
graphic check of catheter placement should be made after
pressure recording is established . As with all invasive diag-
nostic techniques, it is essential to have a clear patient
management goal before balloon flotation catheter monitor-
ing is initiated . Many patients with acute myocardial infarc-
tion now receive thrombolytic therapy early in the course of
the illness . Because central venous catheterization by means
of the subclavian or internal jugular vein is a relative
contraindication to thrombolytic therapy, these sites of
catheter insertion should not be used until the need for
thrombolytic therapy has been established . If the balloon
flotation catheter is indicated, it should be inserted as a
compressible site . Because of the risk of infection, balloon
flotation catheters generally should not remain in the same
site for >48 to 72 h and no longer than clinically indicated .
Recommendations for Balloon Flotation
Right Heart Catheterization in Acute
Myocardial infarction
Class I
I. Severe or progressive congestive heart failure .
2. Cardiagenic shock or progressive hypotension.
3. Mechanical complications of acute infarction, such as a
ventricular septal defect or papillary muscle rupture.
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Class tla
I . Hypotension not responding rapidly to fluid administration
in a patient without evidence of pulmonary congestion,
2
. Before giving a fluid challenge in a patient with circula-
tory insufficiency and suspected pulmonary congestion .
3. As a diagnostic tool when there is suspicion of an
intracardiac shunt, acute mitral insufficiency or pericar-
dial tamponade.
Class Ilb
1 . Patients with acute myocardial infarction who are keno-
dynamically stable, but have evidence of mild pulmonary
congestion .
Class In
I . Patients with acute myocardial infarction who are hemo-
dynamically stable and without evidence of cardiac or
pulmonary complications.
Arterial pressme muMorieg. All cardiac intensive care
units should have the equipment and trained staff to monitor
intraarterial pressure . Arterial monitoring is useful in the man-
agement of hypotensive patients and is required in patients
who are in cardiogenic shock . Long-term arterial pressure
monitoring is most safely accomplished with a small catheter
placed in the radial artery, but other arterial sites, including the
femoral and brachial arteries, are acceptable and may be more
easily catheterized in a hypmensive patient . The arterial circu-
lation of the limb or hand distal to the arterial catheterization
site must be carefully and periodically examined for evidence
of tissue ischemia. Because of the risk of arterial thrombosis
and infection, intrearterial catheters generally should not re-
main in the same arterial site for prolonged periods of time,
certainly no longer than is clinically necessary and never for
>48 to 72 h without being changed. Large artery (brachial or
femoral) catheters placed without a sheath during an emer-
gency should not be left in place for >6 h .
Recommendations for Intraarterial Pressure
Monitoring in Acute Myocardial Infarction
Class I
I . Patients with severe hypotension (systolic <80 mm Hg)
or cardiogenic shock.
2 . Patients receiving vasopressor agents .
Class llu
I . Patients receiving intravenous nitroprusside or other
powerful arterial dilating agents .
2 . Hemodynamically stable patients receiving intravenous
vasodilators for myocardial ischemia .
3 . Patients receiving intravenous inotropic agents-
4 . Patients with life-threatening arrhythmias.
Class III
I . Patients with acute myocardial infarction who are hemo-
dynamically stable .
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Comment: In patients in cardiogenic shock or in those
receiving vasopressor agents, the radial artery pressure may
be artifically low because of constriction of peripheral arter-
ies. This can be recognized by the poor waveform and, in
these patients, a more central arterial pressure may be
required .
Liducaintr
In the presence of acute myocardial infarction, lidocaine
is the drug of choice for the management of ventricular
ectopic beats and arrhythmia, including ventricular tachy
.
cardia and ventricular fibrillation
(35).
Suppression of premature ventricular contractions ap-
plies the concept that with myocardial ischemia, the thresh-
old for ventricular fibrillation is reduced and premature
ventricular contractions may trigger ventricular fibrillation .
Even though premature ventricular contractions in the pres-
ence of myocardial ischemia may be successfully sup-
pressed, ventricular fibrillation may still occur . Moreover,
although lidocane reduces the incidence of ventricular ar-
rhythmia, including ventricular fibrillation, trials (36.37)
have failed to demonstrate that suppression of premature
ventricular contractions significantly reduces overall mortal-
ity in acute myocardial infarction. There appears to be an
increased incidence of asystule with lidocaine and this may
obscure the favorable influence of suppression of premature
ventricular beats (38) .
Generally accepted indications for the use of lidocaine in
acute myocardial infarction include ventricular premature
beats that are I) frequent (>6/min) ; 2) closely coupled (R an
T phenomenon); 3) multiform in configuration
; or 4) occur in
short bursts of three or more in succession . Lidocaine
should also be used for the treatment of ventricular tachy-
cardia and ventricular fibrillation that is resistant to defibril-
lation
.
Dosage. A loading dose or multiple bolus injections are
necessary to initiate lidocaine therapy and to achieve thera-
peutic blood levels rapidly
(39).
An initial intravenous bolus
injection of I mg/kg, not to exceed 100 mg. is recommended .
Additional bolus injections of 0.5 mg/kg can be given every
8 to 10 min if
necessary. to a total of 4 mg/kg . Maintenance
of blood levels is accomplished by the administration of 20 to
50 a/kg per min (1 .4 to 3 .5 mgfmin in a 70 kg patient) . This
produces blood levels oft to
5 pig/ml of blood (40). Patients
who require more than one bolus dose of lidocaine to effect
suppression of extrasystoles may require higher mainte-
nance doses of lidocaine as well (up to 40 to 50 yg/kg per
min) (41).
The elimination is almost exclusively by the liver .
Its half-life averages I to 2 h in normal subjects, >4 h in
patients with relatively uncomplicated myocardial infarc-
tion, >20 h in patients with myocardial infarction compli-
cated by cardiac failure and even longer in the presence of
JACC Vol . 16, No
. 2
August 1990:249-92
cardiogenic shock and, therefore, there will be a need to
reduce the infusion rate of lidocaine appropriately in these
patients (411 .
Patients treated with an initial bolus injection followed by
a maintenance infusion may experience "transient subthera-
peutic plasma concentration at 30 to 120 min after initiation
of therapy . A second bolus injection of 0 .5 mg/kg without
increasing the maintenance infusion rate reestablishes a
therapeutic serum concentration . If arrhythmia recurs afterb
to 10 h (that is, at a steady rate of infusion), a simi?a bolus
injection should be given and the maintenance infusion rate
increased . Increasing the maintenance infusion rate without
an additional bolus injection results in a very slow increase
in plasma lidocaine concentration, taking >6 h to reach a
new plateau (41). The half-life of lidocaine increases after 24
to 48 h (42,43) so the dose should be reduced by I mg/min
preferably at 12 h but at least by 24 It or blood levels should
be monitored, or both.
Toxic reactions should be recognized by frequent and
careful clinical assessment . Reactions are manifested by
central nervous system symptoms such as nausea, drowsi-
ness . perioral numbness, dizziness, confusion, slurred
speech. numbness of lips or tongue, muscle twitching,
respiratory depression or arrest, double vision, tremor and
altered consciousness (44) and cardiovascular effects such as
bradycardia . sinus arrest and hypotension .
Only bolus therapy should be used in the setting of
cardiac arrest. Bolus therapy may be given every 2 to 3 min
as needed. When ventricular fibrillation is present, an initial
dose of I00 mg is recommended . It might take 2 rain for
lidocaine to reach the central circulation (45). In these doses,
lidocaine has no detrimental hemodynamic effects .
Prophylactic administration of Ildocaine in patients with
suspected or proved myocardial infarction . This has been
recommended but is controversial (46) . The adverse effects
of lidocaine used prophylactically may offset any benefits
(47). If routine prophylactic lidocaine administration is to
be
utilized, its use should
be
in those patients at highest risk of
developing ventricular fibrillation. These include younger
patients without prior history of heart failure and who
present within the first 6 h of infarction. Older patients (>70
years) who are at higher risk of developing lidocaine toxicity
probably should not receive prophylaxis routinely and pa-
tients who are seen >6 h after the onset of myocardial
infarction arc less likely to r'_velop ventricular fibrillation
and do not need prophylaxis. Prophylactic use employs a
program of initial repeat small bolus therapy of 0 .5 to 1 .0
mg/kg every 5 min to a total or 200 to 300 mg, followed by an
infusion of 2 mg/min . Prophylactic therapy should be discon-
tinued after the first 12 to 24 h unless other therapeutic
indications are present .
An overview (38), or meta-analysis, of 14 randomized
trials of prophylactic lidocaine in patients with suspected
acute myocardial infarction indicates that treatment may
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reduce the incidence of ventricular fibrillation by 33%, but
provides no evidence of any mortality benefit .
Preventing Lidocaine Toxicity
I . Administration on basis of lean body weight .
2. Caution and reduced infusion rates in :
a) patients >70 years of age .
b) patients with congestive heart failure . cardiogenic
shock or hepatic dysfunction,
c) patients with severe renal dysfunction, and
d) patients with preexisting neurologic dysfunction .
3. Measurement of serum levels with prolonged or high
infusion rates or change in neurologic condition .
When premature ventricular contractions persist despite
administration of lidocaine. procainamide intravenously in
bolus dose" of I to 2 mglkg over intervals of 5 min to a
cumulative dose of approximately 1,00(1 mg, followed by
mairaenance therapy with an intravenous infusion (20 to 80
pg/kg per min), may ba effective (36) .
Recommendations for Lidocaine Use
Class I
1 . in patients with acute myocardial ischemia or infarction,
or both, with ventricular premature beats that are :
a) frequent (>61min)
.
b) closely coupled (R on T),
c) multiform in configuration, or
dl occurring in short bursts of three or more in succes-
sion .
2 . In the patient with ventricular tachycardia or ventricular
fibrillation, or both, in association with defibrillation and
cardiopulmonary resuscitation as indicated .
ON 1111
I . In patients with suspected acute myocardial infarction or
ischemia, or both, with indications as in Class I .
Clare III;
1 . Prophylactic administration in the presence or uncompli-
cated acute myocardial ischemia or infarction, or both .
without ventricular premature beats in patients <70 years
of age and within the first 6 h of onset of symptoms .
Class III
I . Patients with proved allergic or hypersensitivity reactions
to lidocaine .
Although the treatment of choice for ventricular arrhyth-
mias during the acute phase of myocardial infarction is
lidocaine, an occasional patient may be refractory to
lidocaine or the arrhythmia may persist past the acute phase .
Discussion of the pharmacotherapy of these arrhythmias is
beyond the scope of this report, other than to suggest that
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procainamide and quinidine are probably the drugs of
choice. For discussion of the indications for electrophysio-
logic study for selection of dings, the reader is referred to the
ACC/AHA Guidelines for Clinical Intracardiac Electrophys-
iologic Studies (48) .
Similarly, for indications for implantable defibrillators,
the reader is referred to the ACC/AHA Guidelines for
Permanent Cardiac Pacemaker Implantation (in press) .
Supraventricular arrhythmias, although relatively fre-
quent, and rarely life-threatening . When complicating acute
infarction, their management as a rule does not differ from
that for similar arrhythmias complicating other cardiac dis-
orders. The discussion of therapy of these ar hythmias is
similarly beyond the scope of this report
.
Use of Pacemakers in Acute
Myocardial Infarction
Although it is difficult to demonstrate statistically signif-
icant improvement in survival with use of temporary pacing
in acute myocardial infarction, there are accepted indica-
tions and the general impression that some patients are
saved
(49) . Patients with progressive heart block usually
have a large infarct and it is the loss of myocardium that
leads to death in many temporarily saved by pacing . There is
a small but significant incidence of complications from
temporary pacing and this includes induction of arrhythmias,
ventricular perforation, poeumothorax, hemothorax, arterial
injury and infection (50) . Practical external pacemakers that
can
be used for standby indications or in an emergency until
transvenous pacing can be
established are now available
(51) . Temporary pacemakers are also useful for overdrive
pacing of ventricular tachycardias and conversion of su-
praventricular tachycardias such as atrial flutter (52)
.
When
ventricularfanction is severely compromised, AV sequential
pacing to preserve atrial augmentation should
be considered.
Recommendations for Temporary Pacemaker in
Acute Myocardial Infarction
Class I
I
. Asystole .
2
. Complete heart block
.
3. Right bundle branch block with left anterior or left
posterior hemiblock developing in acute myocardial in .
farction.
4 . Left bundle branch block developing in acute myocardial
infarction .
5. Type 11 se: and degree AV block .
6. Symptomatic bradycardia not responsive to atropine.
Class 112
1
. Type I second degree AV block with hypotension not
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responsive to atropine
. During ventricular pacing, if
ventricular atrial conduction causes the atrial contraction
to fall within ventricular contraction, atrial or AV sequen-
tial pacing may be necessary.
2 . Sinus bradycardia with hypotension not responsive to
atropine.
3 . Recurrent sinus pauses not responsive to atropine
.
4 . Atria) or ventricular overdrive pacing for incessant ven-
tricular tachycardia.
Class IIb
1 . Left bundle branch block with first degree heart block of
unknown duration.
2
. Bifascicular block of unknown duration .
Class III
1 . First degree heart block .
2 . Type I second degree AV block with normal hemodynam-
ics.
3 . Accelerated idioventricular rhythm causing AV dissocia-
tion.
4 . Bundle branch block known to exist before the myocar-
dial infarction .
For the use of permanent pacemakers following acute
myocardial infarction, the reader is referred to the ACCI
AHA Guidelines for Permanent Cardiac Pacemaker Implan-
tation
(53), which have recently been revised and are in
press.
Transportation
Although these guidelines focus predominantly on inter-
hospital transportation, the problem of initially transporting
a patient with suspected acute myocardial infarction to the
hospital is highly important. If paramedics are available, it is
most advisable to call for their help . Stabilization of the
patient's condition at the scene by the paramedical team and
direct communication with a physician at the receiving
hospital emergency room can both be accomplished . Trans-
portation in a fully equipped ambulance or mobile coronary
care unit further enhances safety . Transportation in an
automobile may be hazardous and should be
avoided.
Because time is critical for our current therapies, it is
recommended that each community organize a transporta-
tion system to bring the patient quickly for immediate care,
which might include thrombolysis . lithe hospital designated
for initial care is not equipped for more definitive treatment,
a more sophisticated transportation system should be devel-
oped for transfer of patients to a hospital where such
facilities exist .
Hospital plans. Each hospital should have an approved
plan for treating early acute myocardial infarction
. When
notified by the paramedical team that a patient with sus-
pected acute infarction is on the way, the proper personnel
and equipment should be mobilized and the physician qual-
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ified to make the decisions as to use of thrombolytic or other
aggressive therapy should be called in .
Each hospital referring patients or receiving referrals of
patients for completion of definitive or staged early therapy
of acute myocardial infarction must have approved plans for
transportation. If interhospitai transfer is necessary, the
patient should be referred to the most appropriate regional
hospital on the basis of medical needs, facilities and exper-
tise available and consistent with patient choice . A patient in
unstable condition should be transferred only when the
receiving hospital has special skills, services and equipment
required by the patient's condition but not available at the
sending hospital . Transfer should be arranged on a physician
to physician basis. The patient must be accompanied by a
complete medical record (54) .
Emergency transportation must be in a vehicle equipped
and staffed for advanced life support. Inordinate delays at
the sending facility should be avoided, but stabilization of
the patient's condition should be achieved to the extent
possible before and during transportation of the patient to
the receiving hospital . A physician need not accompany the
patient during transportation, but must see to it that the
patient is in stable condition before transfer and will be
treated quickly by a physician on arrival at the receiving
hospital.
Direct voice communication with the receiving hospital is
essential during transportation . Radio contact assures rapid
access to medical direction. Electrocardiographic monitor-
ing and emergency medications are essential . Equipment for
endotracheal intubation and suction, esophageal obturator
airway maintenance, direct current defibrillation and exter
nal pacing are necessary (55).
Patients who should be transferred include (but are not
limited to) those who have undergone acute thrombolysis
and continue to experience angina or other evidence of
continuing ischemia of viable myocardium. These patients
should be in a facility with the staff and equipment required
to perform coronary angioplasty and emergency cardiac
surgery .
Air versus surface hvnspertatlon . During transportation,
safety of the patient and personnel are of foremost impor-
tance
. If the patient's condition has been stabilized and if
thrombolytic therapy has been given, haste in the transpor-
tation process is secondary to safety. Whether transporta.
tion is by surface or by air will depend on the distance and
local capabilities
. Studies (56) of helicopter transfer of pa-
tients with acute myocardial infarction who have or have not
received intravenous fibrinolytic therapy have indicated that
this can
be done safely . Arrhythmias, hypotension and
bleeding have been treated during transit without mortality
(56) .
The advantage of helicopter transport pertains as much if
not more to the personnel and equipment for communication
as to this specific mode of transportation. Aircraft safety is
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an important and controversial issue and costlbenefit ratio is
still being determined. Crashes, deaths and injuries have
occurred during aeromedical transport of critically ill pa-
tients.
1f surface transportation to the receiving hospital required
>90 to 120 min, air transportation should be considered .
Transportation has been performed safely by ambulance for
approximately 60 miles with a paramedic but no physician in
attendance (57)
. In one series (51,58), 33% of patients
developed complications including ventricular arrhythmias
requiring cardioversion, myocardial infarction or hypoten-
sion requiring treatment during transport ; only I of 50
patients died
.
It is important to utilize the following pretransfer check-
fist to avoid mishap and anticipate problems (59) :
Review reasons for transfer with the patient, patient's
family and excepting physician .
Discuss transfer and plans for the patient at the receiving
hospital with appropriate physicians, hospital admin-
istrators and coordinators.
Duplicate appropriate portions of the patient's medical
record.
Review patient care with authorized representatives of
transporting team and carrier .
Provide for continuation of therapy during transportation .
Assure that appropriate medical supplies are available
during transportation and that equipment is functional .
Select suitable medical and support staff to accompany
the patient.
Formulate a realistic and efficient transfer schedule and
arrange for timely linking or support vehicles if more
than one mode of transfer en route is necessary . Police
escort through intracity transfer may be indicated .
Recommendations for Transportation
Transfer to a tertiary care facility equipped for angio-
plasty and cardiovascular surgery is indicated in :
Class I
1 . Patients with recurrent pain .
2
. Patients who have hemodynamic instability as manifested
by persistent congestive heart failure, arterial hypoten-
sion or cardiogenic shock
.
3. Patients with resistant, recurrent ventricular arrhythmias
(ventricular tachycardia or fibrillation) .
Class Da
1 . Patients with high risk myocardial infarction and con-
traindications to thtombolytic therapy, but in whom it is
reasonable to expect that reperfusion can be accom-
plished by percutaneous transluminal coronary angio-
plasty or coronary artery bypass grafting within 6 h .
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2. Patients who are stable late in the initial hospitalization,
but who are to be evaluated for angioplasty or bypass
grafting before discharge.
3
. Patients in the early hours of acute myocardial infarction
who have had prior bypass grafting and who are thought
to be candidates for angioplasty or regrafting .
Class III)
I . Patients who are in stable condition in the early hours of
acute myocardial infarction after thrombolysis but are in
a facility in which coronary angioplasty or surgery cannot
be performed .
2 . Stable patients with early acute transmural infarction and
extensive ST-T changes.
Detection and Quantification of Acute
Myocardial Infarction
A strong history of the typical manifestations of myocar-
dial ischemia and positive risk factors coupled with salient
physical findings of acute myocardial infarction are of ines-
timable value in diagnosis . With a suggestive history, the
probability of infarction is enhanced in the presence of
detectable ventricular ectopic activity, sinus tachycardia,
bradycardia or accelerated idioventricular rhythm
. Findings
that more directly reflect myocardial igjury are palpable
dyskinesia, pulsus altemans, hypotension, a soft S
I , para.
doxic splitting of S2 , an accentuated S4 or an S3, murmur of
mitral regurgitation and signs and symptoms of congestive
heart failure. Manifestations of excessive autonomic ner-
vous system activity support the diagnosis. Involvement of
the right ventricle in patients with inferior infarction is often
recognizable by ST segment changes in ECG leads V3
R and
V4R, elevated venous pressure and hypotension dispropor-
tionate to left heart failure . The Killip classification has been
useful for clinical assessment of the severity of infarction .
However, more objective and definitive information can be
acquired with noninvasive techniques (for example, two-
dimensional echocardiography or radionuclide ventriculog-
raphy) that permit serial assessment, quantification and
localization of regional wall motion abnormalities and delin-
eation of global left and right ventricular function (60) .
Definitive diagnosis is based on Objective criteria ; despite
the occasional occurrence of electrocardiographically silent
infarction, there are frequently nondiagnostic ECG changes
and, therefore, sequential ECG changes remain a mainstay
of early diagnosis
. Infarction cannot be established with
certainty in the absence of alterations of the QRS complex,
but ST segment deviation, T wave abnormalities, intraven-
tricular conduction delays, changes indicative of right ven-
tricular infarction in right-sided precordial leads and nonspe-
cific changes in rate and rhythm are suggestive of infarction .
Laboratory criteria. Detection of the release of macro-
molecules from irreversibly injured myocardium . This has
evolved as the definitive diagnostic criterion of infarction .
2
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Enzymes that egress from ischemic myocardium within
several hours after the onset of irreversible injury include
aspartate aminotransferase, lactate dehydrogenase and cre-
ative kinase (CK). Elevated activity in plasma is a sensitive
diagnostic criterion, although its specificity is somewhat
limited because of potential liberation of enzyme .:om skel-
etal muscle or other tissues . The MB isoenzyme of creatine
kinase has become a cornerstone of diagnosis because it is
much more abundant in myocardium than in most other
human tissues (61) . Necrosis of <0.1 g of myocardium can
be recognized . Assessment of posttranslational conversion
of individual isoenzymes of creatine kinase to subforms
(isoforms) provides criteria for even earlier detection of
infarction and permits recognition of recanalization by in-
creased washout of the tissue subform into plasma (62-64) .
Analysis of isoenzymes of other enzymes such as lactate
dehydrogenase provides less specific information . These
macromolecules are elaborated from components of the
inflammatory response accompanying infarction and hc .zor-
rhage within the heart as well as from the myocytes them-
selves.
Assays of macromolecules such as myosin light chains
(65) and myoglobin (66). Such assays may he valuable in
clarifying elusive diagnoses because of their characteristic
rates of appearance and disappearance. Interpretation of
changes in plasma concentrations of macramolecular mark-
ers of infarction may be obscured when rates of release are
altered by recanalization or profound ischemia . When ap-
pearance rates are very slow compared with disappearance
rates, dilution of the marker in plasma may mask elevations
that otherwise would be apparent
(61).
Sequential changes in plasma concentrations of macro-
molecular markers such as creative kinase are useful in
estimating the extent of infarction (61). In view of the
specificity and sensitivity of the MB isoenzyme of creatine
kinase in plasma as a marker of myocardial injury, assay of
other plasma enzymes is generally not necessary . These
assays may be useful when a patient with suspected infarc-
tion is admitted several days or more after the onset of
symptoms, by which time MB CK elevations may no longer
persist, or if the time of onset of infarction is uncertain (61) .
Isoform analyses
. Recent recognition (62-64) of iso-
forms and characterization of the kinetics of their formula-
tion in plasma by proteolysis of isoforms released from the
myocardium underlie an approach for very early detection of
infarction and noninvasive detection of reperfusion . Al-
though creatine kinase isoform and myoglobin analyses are
still investigational, likely uses are monitoring the efficacy of
pharmacologic thrombolysis, defining the need for invasive
studies or interventions and facilitating interpretation of
episodes of chest pain . Elevations of the ratio of the tissue
MM CK isoform (MM1) to the fully converted form in
plasma
(MM) or of myoglobin in samples obtained within I
h after such an episode compared with values in samples
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obtained before the episode are consistent with recurrent
infarction.
Ventricular performance. Assessment by echocardiog-
raphy and radionuclide and contrast ventriculography . Re-
gional hypokinesia or dyskinesia may be a manifestation of a
condition other than infarction and certain infarcts may not
be reflected by detectable or proportional wall motion ab-
normalities . Despite these provisos, both the sensitivity and
the specificity of abnormal wall motion as a criterion of acute
myocardial infarction exceed 90% with several imaging
methods.
Two-dimensional echocardiography consistently local-
izes impaired wall motion associated with anterior infarcts
and that associated with inferior infarcts in >90% of patients
(67). Contrast echocardiography may permit estimation of
the extent of infarction by delineating hypoperfusion in the
region at risk, although its use for this purpose is primarily in
research and its implementation requires a practiced tech-
nique and dedicated instrumentation (68) .
Wall thinning or
the lack of wall thickening is an important ancillary finding.
Global measures of left ventricular performance are less
sensitive and specific than assessments of regional wall
motion in detecting, localizing and qualifying the extent of
ischemic insults.
Assessment of global and regional ventricular perfor-
mance by radionuclide ventriculography has a sensitivity
and specificity comparable with those of echocardiography
and provides estimates even in patients with anatomic lea-
lures precluding adequate echocardiographic examination .
Cost and radiation exposure are considerations (69).
Sensitivity, specificity, spatial resolution and quantitative
power of contrast ventriculography are superior to those
with any conventional noninvasive method. Expense, radi-
ation exposure and risk associated with left heart catheter-
ization and administration of radiographic contrast agents
are disadvantages .
Assessment by clue computed tomography and nuclear
magnetic resonance imaging. Several novel techniques have
been developed for delineating abnormal ventricular function
indicative of acute myocardial infarction, including ulrrafast
(tine) computed tomography (70). Instrumentation is expen-
sive, radiation burdens are significant and applicability is
limited. Gated nuclear magnetic resonance (NMR) imaging
with or without paramagnetic contrast agents such as gadolin-
ium-DTPA detects reversible and irreversible myocardial in-
jury induced by ischemia in experimental animals and patients
(71).
Spin-echo images show increased signal intensity corre-
sponding with dyskinetic segments, reflecting acute myocardial
infarction (72) or zones with diminished perfusion evident in
contrast studies (71). NMR imaging provides excellent spatial
resolution, but the costs of instrumentation, the current need
forrelativelylongima ingintervalsandthedifficultiesinherent
in imaging patients instrumented with metallic devices are
disadvantages that often preclude its use for diagnosis of acute
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myocardial infarction
. However, rapid speed NMR imaging
may soon be available to enhance the capability for imaging
cardiac dynamics .
Sdntigraphic methods for detesting infarction and ische-
mia
.
Infarct-avid agents such as technetium-99m pyrophos-
phate detect infarction sensitively and define its locus (infarct
scintigraphy)
. Disadvantages include the lack of accumulation
of tracer in tissue early during the course of infarction and,
hence, reliable detection only 24 h or more after onset
. Radio-
labeled monoclonal antimyosin antibodies (Fab fragments la-
beled with indium-111 or technetium-99m) bind to myosin in
irreversibly injured cells and yield excellent images of an
infarction
. However, positive results can be obtained only after
injury has evolved, and uptake of tracer may be influenced
markedly by the hypoperfusion in the infarct zone . Decreased
uptake of potassium analogs such as thallium-201 indicative of
hypoperfused or necrotic tissue can be implemented earlier,
and differentiation of reversible from irreversible injury can be
accomplished by acquisition of "redistribution" images in
which differences between accumulation of tracer in normal
zones and those with initially depressed accumulation v anish .
i n part because of differential washout rates (perfusion scintig-
raphy) (69). As a current research scintigraphic method, the
use of technetium-99m isonitrile, which does not redistribute .
may become a useful method for assessing the initial zone at
risk and the success of reperfusion (73
.74) .
Echocudiographlc methods for assessment of patients with
infarction . Echocardiography is of considerable value in the
assessment of patients with acute myocardial infarction for
acquisition of prognostic information as well as for charac-
terization of ventricular function . In patients with apparent
complications of infarction, echocardiography is particularly
useful in determining the presence or absence of pericardial
effusion compromising cardiac performance : characterizing
factors that contribute to otherwise unexplained tachycar-
dia, hemodynamic instability or pulmonary congestion sug-
gestive of pump failure; assessing the severity of and iden-
tifying factors that may require alteration of medical
management of infarction, such as coexisting valvular or
congenital heart disease
; and defining the extent to which
potentially catastrophic complications may be contributing
to sudden deterioration in the clinical course, such as mitral
insufficiency, ventricular septal rupture
. cardiorhexis with
hemopericardium or ventricular aneurysm . In patients with
extensive anterior myocardial infarction (ECG criteria and
peak MB CK >150 lUAiter [or total CK > 1 .000 IU/liter]),
echocardiography may be particularly helpful in assessing
hypokinesia or dyskinesia predisposing to left ventricular
mural thrombi, detecting thrombi already present and facil-
itating assessment of the predisposition of thrombi for em-
bolization. In patients in whom left bundle branch block, a
paced rhythm, posterior infarction or non-Q wave infarction
is present, the diagnostic power of the ECG for infarction
may be somewhat limited . Under these circumstances. d e-
GUNNAR
ET AL
.
	
261
ACCtAt4A TASK FORCE REPORT
section of infarction and delineation of its locus and extent
can be facilitated greatly by echocardiography .
Blagaosk of acute
myoardld blared... In addition to
history and physical examination, patients with suspected
acute myocardial infarction should be evaluated with a chest
X-ray study
. serial ECGs, possibly several within a few
hours, and MB CK determinations 175)
. Subsequent ECGs
are needed daily until the nature of evolution of infarction is
defined and more frequently if complications occur
. Plasma.
MB CK (or total CK if MB assays are not available) should
be measured at 6 h intervals for the first 24 h and then daily
until the diagnosis is established or,
in the absence of
complications, until values have returned to baseline . Deter-
mination of levels of other plasma enzymes, such as aspar-
tate aminotransferase and lactate dehydrogenase, are not
necessary except in unusual circumstances such as when
admission is days after suspected infarction at a time lactate
dehydrogenase may still
be elevated but MB CK has re-
turned to normal .
Indications for assusment ofleft veMrlcWar function is the
early phase of acute myocudlW idarctfoa, Assessments of
left ventricular function can
be made expeditiously by echo-
cardiography, radionuclide ventriculography and other im-
aging techniques
. The selection of the particular modality
used in a given institution should depend in patt on the
familiarity and expertise of the institution with each specific
method. It is inappropriate to acquire duplicate information
with different methods unless specifically indicated
.
Recommendations for Echocardiography in the
Early Phase of Acute Myocardial infarction
Class I
1 . Myocardial infarction associated with shock or profound
pump failure consistent with extensive myocardial dys-
function or a potentially surgically remediable lesion such
as ventricular septal rupture . free wall rupture, profound
mitral regurgitation or left ventricular true or pseudoan-
eurysm.
2 . Myocardial infarction associated with extensive infarc-
tion (ECG localization and peak MB CK > 150IUlliter for
total CK >1,000 IUAiter]) in which valuable prognostic
information and information regarding the need for anti-
coagulant therapy for prevention or treatment of ventric-
ular thrombi can be acquired.
3 . Myocardial infarction accompanied by clinical complica-
tions such as tachycardia, hemodynamic instability, pul-
monary congestion suggestive of pump failure, refractory
angina or pericardial tamponade .
4 . Myocardial infarction associated with vnlvralarorcongen-
ital heart disease .
5
. Suspected pericarditis or pericardial effusion that may
complicate acute myocardial infarction .
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6. Myocardial infarction in patients being or to be treated
with calcium antagonists or betgadrenergic blocking
agents in whom left ventricular function may be compro-
mised so that risks and potentially deleterious effects of
therapy can be anticipated or recognized promptly .
Class Ha
1 . Myocardial infarction superimposed on previous infarc-
tion or associated with ECG phenomena such as left
bundle branch block or posterior locus that may obscure
diagnosis, in which case delineation of regional wall
motion abnormalities may help confirm the diagnosis and
provide prognostically important information
.
2 . Myocardial infarction with suspected concomitant right
ventricular infarction (such as true posterior infarction) to
define the severity of right ventricular involvement as a
guide to management and exclude pericardial tamponade
.
Class lib
1 . Myocardial infarction of modest extent without clinical
complications for evaluation of prognosis .
Use of Beta-Blockers in Acute
Myocardial Infarction
Beta-blocker therapy in acute infarction requires consid-
eration in relation to two goals:
l . Limitation of
myocardial damage or mortality, or both,
when administered during the first few hours of infarction .
2 . Reduction of the risk of reinfarction or mortality, or both,
when administered after completed infarction
.
Lhnitatkin of myocardial damage or mortality, or both,
when beta-blocker therapy isslarted during the first few hours
ofinfarction . Studies of reperfusion have convincingly dem-
onstrated that the amount of myocardial damage is not fixed
during the first few hours of acute infarction
. Beta-blocking
agents can potentially reduce myocardial oxygen demand
during this period by reducing heart rate and arterial pres-
sure or myocardial contractility, or both, and have a favor-
able influence on myocardial blood flow distribution
. The
prolongation of diastole resulting from a reduction in heart
rate may augment the amount of coronary flow reaching
injured but not irreversibly damaged myocardium (particu-
larly in the subendocardium) . One might therefore expect
that beta-blockade could increase the amount of myocar-
dium salvaged by reperfusion if it was achieved sufficiently
early in the course of infarction. There is evidence that
beta-blockade can reduce the extent of infarction or the
complications of infarction, or both, in the absence of
thrombolytic therapy .
Nearly 30 randomized trials have now been reported
(76-78) using an initial intravenous dose of a beta-blocker in
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acute infarction without concomitant thrombolytic therapy .
In the largest of these (77), in which >16,000 patients were
accepted within 12 h of the onset of symptoms, the 7 day
mortality rate was reduced from 4.3% to 3 .7% (p < 0.02) .
Favorable trends of similarmagnitude were also apparent for
reinfarction and cardiac arrest (or ventricular fibrillation) .
The 14% mortality difference between the treated and non .
treated groups was apparent by the end of day I and
remained essentially constant thereafter . Beta-blockade was
initiated in this study as 5 to 10 mg of atenolol (intravenous-
ly) and continued at a level of 100 mg orally/day for 1 week.
In the second largest study (78), the 15 day mortality rate in
>5,700 patients was reduced from 4.9% to 4 .3%, with the
difference in mortality between treated and placebo groups
again evident at day 1 . It was suggested that the beneficial
effect of beta-blockade was largest in "high risk" subgroups,
as defined by either prestudy risk predictors or a multivariate
risk model
. The beta-blocker employed was metoprolol in a
dose of up to 15 mg intravenously in three divided doses
(with 2 min intervals between) and, starting l5 min after
completion of the intravenous dosage, 50 mg orally every 6
h for 48 h then 100 mg twice daily thereafter .
Assessment of effects of acute beta-blockade on indexes
of infarct size are complicated by differences in study design
(for example, frequency of enzyme sampling, time of itdda-
tion of beta-blockade in relation to onset of symptoms,
approaches to ECG evaluation) mid study size. Review of
available studies (76) is consistent with the view that modest
favorable effects occur. Thrombolytic agents were not ad-
ministered in these studies .
A recent trial (79) of early beta-blockade in conjunction
with thrombolytic therapy showed no adverse effect of the
combined therapy and a suggested reduction in frequency of
reinfarction compatible with findings in the larger studies
(76-78).
Because several beta-blocking agents (both cardioselec-
tive and nonselective) have been employed in the studies
cited, beneficial effects of beta-blocking agents do not seem
limited to any particular member of the drug group. Agents
having intrinsic sympathomimetic activity as well as beta-
blocking activity may be less desirable and should be
avoided. Intravenous beta-blocking agents with extremely
short durations of activity may prove advantageous in se-
lected patients .
Contraindicatkms to Beta-Blockade
Heart rate <60 beatslmin .
Systolic blood pressure <100 mm Hg.
Moderate to severe left ventricular failure .
Signs of peripheral hypoperfusion .
AV conduction abnormalities : PR interval >0
.22, type I
and II AV block or complete heart block.
Severe chronic obstructive pulmonary disease .
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Relative Contraindications to Beta-Blockade
History of asthma.
Current use of beta-blockade (may require modification
of initial intravenous dosage)-
Current use of calcium channel blockers (verapamil and
diltiazem).
Severe peripheral vascular disease.
Difficult to control insulin-dependent diabetes .
Recommendations for Early Intravenous
Beta-Blockade
Class I
I . Patients, including those receiving thrombolytic therapy .
with reflex tachycardia or systolic hypertension . or both,
without signs of congestive heart failure or contraindira-
don to beta-blockade .
2 . Patients with continuing or recurrent ischemic pain, ta-
chyarrhythmias such as atria] fibrillation with a rapid
ventricular response or an enzyme elevation thought to
represent recurrent injury who are without contraindica-
tion to beta-blockade .
3. Postinfarction angina while awaiting study in patients
without contraindications .
Clans Ill
1 . Other patients without contraindication to beta-blockade
who can be treated within the first 12 h from the onset of
chest pain.
2. Non-Q wave myocardial infarction.
C111115111111
1 . Patients with moderate to severe left ventricular failure
and other contraindications to beta-blockade
.
Reduction of the risk of refofardlen or mortality, or both,
when maintenance beta-bloc er therapy Is given after com-
pleted infaredon. A number of placebo-controlled second-
ary prevention trials (76,80,81) involving >35,000 patients
indicate that chronic beta-blockade begun in the early phase
of infarction improves survival and decreases the incidence
of reinfarction for at least the first several months after the
acute event . The improved survival appears to include a
reduction in the frequency of sudden cardiac death . Patients
with compensated or mild congestive bean failure appear to
benefit as greatly as patients without heart failure and may
show a significant reduction in the frequency of sudden
cardiac death (78). Patients with an uncomplicated course
after an initial infarction, good residual left ventricular
function, no angina or arrhythmia and no evidence of ische-
mia during functional testing are recognized to have a very
favorable 1 year mortality rate, making the benefit of sec-
ondary prevention by long-term beta-blockade less clear in
this group .
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The absolute reduction in the 2 year mortality rate
effected by long-term beta-blockade in patients without
contraindication to this therapy appears to be 2% to 3% (for
example, a reduction in one major trial
1801 from 9.8% to
7.2% over an average 25 month follow-up period). The
favorable effect of beta-blockade again occurs with both
cardioselective and nonselective agents . However, agents
with intrinsic sympatlomimetic activity should be avoided .
Daily dosages in the studies demonstrating beneficial effects
of beta-blockade have again been relatively high (toe exam-
ple, 180 to 240 mg of peopanolol [801 and 20 mg of timolol
(811), but there is no evidence that the same results cannot be
achieved with lower doses . Whether or not low risk parents
should be routinely treated with beta blockade has been a
subject of some debate because there is concern about side
effects of these agents and the greatest effect can be demon-
strated most readily in the high risk patients. Side effects
(fatigue, depression or sexual dysfunction, nightmares and
insulin dosage
difficulty) may be frequent enough in low risk
patients to outweigh benefits . Goldman et al . (82) presented
cost-effectiveness data suggesting that even low risk patients
derive significant benefit; however, this theoretic analysis
did not take into account the psychosocial costs of the side
effects . Finally, none of the studies cited addresses the
question as to if and when the recommendations should be
modified in patients who have had successful revascularize-
tion after myocardial infarction .
Recommendations for Long-Term Beta-
Blockade for Secondary Prevention in Patients
Without Myocardial Revascularization
Class I
l. All but low risk patients who do not have a clear
contraindication to beta-blockade . Treatment should or-
dinarily begin within the first few days of infarction and
should be continued for at least 2 years .
Class Ha
I
. Low risk patients who do not have a clear contraindica-
tion to beta-blockade . Treatment to begin within the first
few days of infarction and continued for at least 2 years .
Decisions concerning beta-blockade withdrawal (or dose
reduction) because of drug side effects should take into
account the risk status of the individual patient (that is,
the decision to reduce or discontinue should be controlled
by weighing side effects more heavily as one moves from
high to low risk patients)
.
Clots III
1 . Patients with contraindications to beta-blockade
.
Calcium Channel Blockers
A wealth of published data have accumulated describing
the efficacy of calcium channel blocking drugs as anti-
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ischemic agents effective in the treatment of stable and
unstable angina pectoris resulting from fixed stenoses of
coronary atherosclerosis and from coronary vasospasm . The
known cardiovascular properties of these drugs suggest a
rationale for their use in the treatment of acute myocardial
infarction and in the prevention of secondary complications
after myocardial infarction . Although some new calcium
channel blocking drugs are under investigation, this discus-
sion will be limited to those now in clinical use -verapamil,
nifedipine and diltiazem
. All three reduce systemic vascular
resistance and, therefore, are utilized as antihypertensive
agents (83) . They have been shown to influence the ionic
calcium currents that regulate action potential (64) . Dilt-
iazem and verapamil both reduce myocardial contractility,
thereby diminishing myocardial
oxygen consumption, as
does nifedipine if reflex sympathetic stimulation is blocked
(85). Diltiazem and verapamil have potent effects on the AV
node, producing slowing of the ventricular response to atria)
flutter and fibrillation, terminating paroxysmal supraventric .
ular arrhythmias and occasionally producing AV block .
Despite these multiple cardiovascular effects of the cal-
cium channel blockers, there have been only a few reports
(86,87) evaluating their use in acute myocardial infarction
.
Dif iazem. The Diltiazem Reinfarction Study Group (88)
reported that in the dose of 90 mg every 6 h, initiated within
24 to 72 h after onset of infarction, diltiazem was effective in
preventing early reinfarction and recurrent angina in patients
with non-Q wave infarction (formerly designated nontrans-
mural or subendocardial infarction) . The study of long-term
diltazem therapy in patients with both Q wave and non-Q
wave myocardial infarction failed to demonstrate a beneficial
effect of diltiazem . Although there were slightly fewer recur-
rent cardiac events overall in the diltiazem group as opposed
to the placebo group, this did not reach statistical signifi-
cance. In patients receiving diltazem, there appeared to
be
an adverse effect in the small group of patients with left
ventricular dysfunction and this may have obscured the
favorable effects in patients with normal ventricular func-
tion, but this was not tested prospectively. Thus, the efficacy
of routine diltiazem treatment after acute myocardial infarc-
tion in patients with preservation of left ventricular function
is not yet established.
Verups nll. This agent may be
beneficial in the setting of
acute myocardial infarction for the treatment of acute su-
praventricu(ararrhythmias, particularly ifotherantiatrhythmic
drugs (such as digoxin) are inadvisable and neither ventricular
function northe conduction system is in jeopardy
. Care should
be exercised in patients receiving beta-blockers .
Nlredipine
. Muller et al. (89) reported the results ofa trial
to determine whether early nifedipinc therapy could prevent
progression or extension of infarction as determined by MB
CK values and whether nifedipine would limit necrosis in
patients with ongoing acute myocardial infarction with a
primary end point being the serum enzyme determination of
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infarct size
(89). The results showed no reduction in the
progression to infarction or a reduction of infarct size, but
the nifedipine group had a significantly higher 2 week mor-
tality rate than the placebo group (p < 0.02).
Thus, there is no clear evidence to support the routine use
of calcium channel blockers in the treatment of acute myo-
cardial infarction (90), except in the subset of patients with
non-Q wave infarction, in whom diltiazem was found effec-
tive in preventing early eninfarction and recurrent severe
angina .
Recommendations for Use of Calcium Channel
Blockers in Acute Myocardial Infarction
Class 1
1 . Symptomatic treatment of postinfarction angina while
awaiting cardiac catheterization and therapy based on
angiographic findings .
Class Ha
1 . Diltiazem in patients with non-Q wave infarction in whom
no contraindication exists, It should be started during the
first 48 h and continued through the hospital phase and
the first postinfarction
year.
2. After angioplasty, a calcium channel blocker to prevent
coronary vasospasm.
Class lib
1. A calcium channel Mocker may be used in transmittal Q
wave) infarction for treatment of postinfarction angina,
especially if contraindications to proceeding with coro-
nary arteriography and more definitive treatment exist .
Class m
1. Calcium channel blockers that suppress ventricular func-
tion in patients with myocardial infarction complicated by
pulmonary congestion or left ventricular dysfunction.
Thrombolytic Therapy in Patients With
Acute Myocardial Infarction
Background
. Approximately 66% of heart attack victims
at hospital entry have ST segment elevation, making it likely
that the process is caused by an occlusive coronary clot
. In
patients with this finding, clot-dissolving therapy in the form
of intravenous streptokinase (SK [StreptaselKabikinase]),
recombinant tissue-type plasminogen activator (re-PA [Acti-
vasel) or anisoylated plasminogen streptokinase activator
complex (APSAC [Anistreptase]) can dissolve the clot and
restore flow, interrupt the infarction, reduce myocardial
necrosis and improve survival if therapy is delivered within
6 h of the onset of the attack .
Results of dinical trials, The use of thrombotytic therapy
in acute myocardial infarction with ST segment elevation
rests on reductions in mortality observed in randomized
controlled trials (Table 1).
-p = 0.06-secondary end point
. tPreliminary report. Numbers in parentheses nre references . Theca trials of throeobelytic therapy are presented to sbw
differences in entry criteria as reffeoted in control-related mortality rate . This table should not hr used to compare treatment-mlated mortality rates amoatt trials .
AIMS = APSAC Intervention Mortality Study : APSAC = anisoylated plasminogen streptokinasc activator complex ; ASSET = Arab-Scaodinavibn Study of
Early Thrombolysis; fur Coop = European Cooperative Study ;
GISSI = Gmppo
Italiarm per to Studio ddb Streptochiaui nell'Infano Miocadieo ; ISIS2 =
Second International Study
f Infeuct Survival: n-PA = recombinant tissue-type ptasminooen activator ; SK = nrepiokintea; +I- = with or witbaos .
GISSI. The first large study reported was conducted in
Italy and is known by the acronym GISSI (8,91)
.
In this trial,
11,712 patients presenting within 12 h of the onset of acute
infarction and free of contraindications to thrombolytic
therapy were randomly assigned to treatment with a I h
intravenous infusion of 1.5 million U streptokinase or to
conventional care with no streptokinase. The 21 day mortal-
ity rate in the streptokinase group was 10 .7% compared with
13 .0% in the control group, a significant 18% reduction (p =
0.0002). No benefit was observer: in patients receiving strep-
tokinase >6 h after the onset of symptoms . However, in
those treated within 6 h, the mortality rate at 21 days was
12
.8%p in the control group and 10 .2% in the streptokinase .
treated group (a 20%n reduction in mortality). The earlier
treatment was started, the more effective it was . For exam-
ple, in patients whose treatment started within 3 to 6 h,
streptokinase resulted in a 17% reduction in mortality (from
14.1% to 11 .7%) ; in the 0 to 3 h treatment group, it reduced
mortality by 23% (from 12 .0% to 9.2%) and in those treated
within f h of symptoms by 47% (from 15
.4% to 8
.2%)
. The
survival curves from 21 days to I year are parallel (7%
mortality rate in both treated and untreated groups between
hospital discharge and 1 year), demonstrating extended
benefit in a group of patients marked by very infrequent use
of percutaneous transluminal coronary angioplasty and cor-
onary artery bypass graft surgery.
ISIS-2. The investigators participating in the Second
International Study of Infarct Survival (ISIS-2) (10) have
reported baseline and outcome data in 17,187 patients with
suspected myocardial infarction who were recruited within
24 h of the onset of chest pain . These patients were random-
ized to intravenous Streptokinase (1 .5 mU over 60 min), oral
aspirin (160 mg/day for I month), to both or to neither in a
double-blind fashion by means of matching placebos . Pa-
tients were excluded from the trial if >24 h had elapsed from
the onset of symptoms, whereas most other trials used either
a 6 h or 12 h exclusion, and there was no age limit, which
ranged from 70 to 75 years in other trials
. The issues to be
tested were the effect of streptokinase on the vascular
mortality rate at 5 weeks and later and the effect of aspirin on
the 5 week vascular mortality rate . In addition, a subsidiary
analysis was planned of the effect of streptokinase on the
vascular mortality rate in those treated <4 h after the onset
of pain, 4 to 12 h after pain and at 12 to 24 h.
When the data were analyzed for mortality at 5 weeks
after trial entry, the ISIS-2 investigators (IO) observed that
the 8,592 patients assigned to streptokinase treatment expe-
rienced 786 (9
.1%) vascular deaths compared with 1,016
such deaths (11.8%) in the 8,595 patients assigned to receive
placebo, a 23% reduction (p < 0 .00001)
. This difference is
similar to the overall 18% reduction noted in the GISSI trial
(8,91) .
In the interval between 5 weeks and I year, the
estimated vascular mortality rate in the streptokinase and
placebo groups was 5 .7% and 6.2%, respectively, also sim-
ilar to that in the GISSI trial (7% mortality in both groups in
the interval from 3 weeks to I year)
. The observed 5 week
vascular mortality rate in the streptokinase and placebo
groups was, respectively, 8.2% and 12.1% (32% reduction)
Trial No.
Shun-Term
Modality
Follow-Up
la-.l
(daYS1
%
Reduction
% Reduction in
Subpoups by Tone
toTmtmatt
Treatment
190)
Control
t%)
GISSI (SK)x8.91) 11,712 10.7 13.0 21 I8 6-12 h-3
3-6 h-17
0-3 h-23
<I 6-47
ISIS-2 (SK +/- aspirinol0) 17.187 9.1 11 .8 35 23 12-24 h-I9
4-12 h-13
<4 h-)2
<t h-42
ASSET(rt-PA)!(tll 5 .011 7.2 9.8 30 26 3-5 h-24
<3 6-26
Eur Coop (n-PA + asptdn)I(99) 721 2.3 5.7 14 51` 3-5
h-9
<3 h-82
AIMS (APSAC)I(12)t 1 .004 6.4 12 .2 30 47 4-6 11-52
<4 6-41
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in those treated within 4 h, 10 .3% and 11 .8% (13% reduction)
in those treated between 4 and 12 h and 8 .7% and 10 .8%
(19% reduction) in those treated between 12 and 24 h . In
patients treated within I h, the 5 week vascular mortality
rate was reduced by 42% in the streptokinase group (similar
to the 3 week reduction of 47% in the GISSI trial) . Thus, the
overall ISIS-2 findings confirm the GISSI results . Earlier
treatment appears more effective than late treatment, with
substantial benefit to at least 6 h .
The ISIS-2 entry criteria did not require ST segment
elevation. Review of ISIS-2 entry ECGs revealed that only
56% of the 17,187 patients had ST segment elevation . The
remainder had ST depression (8%), bundle branch block
(6%), Q waves or T wave inversions (27%), or both, or had
a normal study (2%).
ISIS-2 (10) tested 160 mg of aspirin daily for 35 days as an
adjunct to thrombolytic therapy . The first dose was given
immediately after trial entry . In the 8,587 patients assigned
to receive aspirin, there were 800 (9.3%) vascular deaths by
5 weeks compared with 1,002 such deaths (11.7%) in the 8,600
given placebo; this 21% reduction (p < 0.00001) is similar in
magnitude to the result with streptokinase . The vascular mor-
tality rate between 5 weeks and I year was similar (6 .0% and
5
.8% in the aspirin and the placebo group, re eectively).
Finally, a comparison of the group assigned to receive both
streptokinase and aspirin with the group assigned to neither
revealed a 5 week vascular mortality rate of 7.9% (341 of 4,292
patients) and 13 .0% (557 of 4,300 patients), a 39% reduction, (p
< 0 .00001). In addition to confirmation of the GISSI findings
with respect to streptokinase, ISIS-2 provides very strong
evidence for a similar and additive effect of aspirin on subse-
quent mortality in patients with infarction
.
Short-term mortality
. Mortality data from the GISSI and
ISIS-2 studies, with similar smaller supporting trials carried
out in The Netherlands, Federal Republic of Germany, New
Zealand and Washington (state) and the ISIS-2 pilot study
(92-97) provide conclusive evidence that intravenous strep-
tokinase given early in the course of myocardial infarction to
patients without contraindications reduces the short-term
mortality rate by 20% to 30%
. The smaller supporting trials,
in which left ventricular function and infarct size were
assessed, reveal myocardial salvage as assessed by these
two indirect measures of infarct size, supporting the hypoth-
esis that the major mechanism of action of streptokinase is
limitation of infarct size by reperfusion
. Intravenous strep-
tokinase was approved the Food and Drug Administration
for use in patients with myocardial infarction in 1987 .
New Ihrombolylk agents . European Cooperative Study
and TIMI. A new generation of thrombolytic agents that
activate plasminogen preferentially on the surface of clot
rather than in the general circulation (as is the case with
streptokinase) has been employed in clinical trials during the
last 5 years (98).
One of these agents, recombinant tissue-
type plasminogen activator (rt-PA) was approved by the
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Food and Drug Administration in 1987 for use in patients
with acute myocardial infarction . Two other agents, anisoy-
lated plasminogen streptokinase activator complex (APSAC
IAnistreplasel) and single chain urokinase-type plasminogen
activator (SCUPA) are under active investigation . The for-
mer has just been approved by the Food and Drug Admin-
istration, but SCUPA has not as yet been approved for
general use in the United States.
In two independent randomized trials, the patency or reper-
fusion rate, or both, after intravenous rt-PA were compared
with those with intravenous streptokinase . In the European
Cooperative Study (99), 129 patients were given either rt-PA or
streptokinase intravenously an average of 3 h after the onset of
myocardial infarction
. Patency of the infarct-related artery
observed approximately 90 min after initiation of infusion was
70 17v and 55% for the rt-PA and the streptokinase groups,
respectively (p = 0 .058) . The investigators in the National
Heart, Lung, and Blood Institute Thrombolysis in Myocardial
Infarction (TIMI) study used a slightly higher dose of rt-PA and
encountered a longer delay in starting thrombolytic infusion
because of required pretreatment arteriography
. They noted a
patency rate of 70% and 43%, respectively, 90 min after onset
of rt-PA and streptokinase infusion in 290 patients treated an
average of 4.75 h after pain onset (100). Thus, the patency rates
noted by the two groups of investigators were identical for
rt-PA (70%) and varied minimally (55% in the European
Cooperative Study and 43% in the TIMI trial) in the streptoki-
nase groups .
The declared TIMI study end point was, however, the
proportion of patients entering with closed coronary arteries
who experienced reperfusion 90 min after initiation of threm-
bolytic infusion. In 232 TIMI patients with a closed infarct-
related artery, the 90 min reperfusion rate was 62% and 31%
for rt-PA and streptokinase, respectively . In addition, as
noted in both the European and TIMI studies, perturbation
of elements of the clotting system was less marked with
rt-PA, although hemorrhagic complications were similar in
the streptokinase and rt-PA groups and largely due to
hematoma formation at the arterial catheterization site .
Studies after changedformulationojri-PA . Shortly after
completion of the European and TIMI comparisons of rt-PA
and streptokinase, the rt-PA production process was
changed. The new product, predominantly single-chained,
had pharmacokinetic properties that made 100 mg of the new
product roughly equivalent to 80 ing of the product used in
the TIMI study (101). The rt-PA studies discussed next used
the more recent formulation, which is the rt-PA preparation
approved for use by the Food and Drug Administration .
Investigators participating in the Anglo-Scandinavian
Study of Early Thrombolysis (ASSET) (11) randomized
5,011 patients with suspected myocardial infarction within 5 h
of onset to either 100 mg of rt-PA (10 mg bolus injection, 50 mg
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in the first hour, 20 mg in the second and third hours) or
placebo. Aspirin was not given. The ASSET investigators
made no ECG entry criteria, but excluded patients >75 years
of age. Approximately 18% of ASSET patients had a normal
ECG at trial entry . At I month, the total mortality rate in the
it-PA-assigned group was 7 .2% compared with 9 .8% in those
assigned placebo, a 26% reduction (p = 0 .0011) (11) .
The European Cooperative Group (102) reported a ran-
domized, double-blind, controlled trial comparing rt-PA (100
mg given over 3 h) with placebo in 721 patients with chest
pain and ST segment elevation entered within 5 h of symp-
tom onset . Both groups received aspirin and heparin. The
study was designed to detect a difference in left ventricular
function
. Death at 14 days and death at 3 months were
declared as secondary end points . The 14 day mortality rate
was 2
.8% (10 of 355) in the group assigned to rt-PA and 5 .7%
(21 of 366) in the placebo group. This observed 51% mortal-
ity reduction is of borderline statistical significance (p =
0.06). Thus, the European collaborative group noted a
substantial reduction in the 14 day mortality rate, but this
was of borderline statistical significance in a trial not de-
signed to test a mortality difference
. Ejection fraction, the
declared primary end point, was 2 .2 ejection fraction points
higher (95% confidence interval 0 .3 to 4 .0) in the rt-PA group
compared with the placebo group (50.7 versus 48.5, respec-
tively). Infarct size as assessed by cumulative release of
hydroxybutyrate dehydrogenase was reduced by 20% in the
rt-PA group compared with the placebo group (p = 0
.0018)
.
Neither of these two trials designed to compare patency
or reperfusion of streptokinase and rt-PA was sufficiently
large to detect a statistically significant mortality difference .
Thus, these trials that have directly compared rt-PA and
streptokinase demonstrated that at 90 min and with the doses
given, rt-PA is a more effective coronary thrombolytic agent
with less consumption of clotting factors . The recent com-
parison of streptokinase and n-PA reported from New
Zealand (103) was designed to test the effect of the two
agents on ventricular function . The study was a double-blind
trial comparing the effect of r-PA with streptokinase on
subsequent (3 week) ventricular function in 270 patients
admitted within 3 h of their first myocardial infarction . A
similar ejection fraction was noted (0.58 in both rt-PA- and
streptokinase-assigned groups), but mean ejection fraction
was not adjusted for patients with an undetermined ejection
fraction (such as patients who died before the scheduled
ejection fraction determination) . The mortality rate at 30
days was 3 .7% in the rt-PA group and 7 .4% in the strep ....i-
ease group (p > 0.2) .
Although there were fewer deaths in
the rt-PA group than in the streptokinase group, the trial
(103) was too small to draw conclusions about mortality .
The mechanism of mortality reduction with both n-PA
and streptokinase is likely to be thrombolysis with resultant
reperfusion. limitation of
infarct size and improved 1'ft
ventricular remodeling. Accordingly, one might anticipate
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myocardial salvage and mortality reduction with rt-PA sim-
ilar to and perhaps larger than that observed with streptoki-
nase, given the observed reperfusion advantage observed
with rt-PA
. There are currently two large randomized trials
involving a direct comparison of streptokinase and rt-PA
using death as an end point . G1SSl-2 is nearing completion
and will probably report data in 1990, while ISIS-3 is early in
patient recruitment. Until these large trials are completed,
clinicians must shoulder the burden of choosing between
streptokinase and rt-PA without e onclusive comparative
data on relative morbidity and mortality, bearing in mind the
substantial cost and reperfusion differential .
The AIMS Trial Study Group O2)
. This group, in the
United Kingdom, conducted a multicenter, double-blind,
placebo-controlled evaluation of APSAC (30 U intrave-
nously over 5 min) in patients <70 years of age admitted with
a30 min but not >6 h of chest pain associated with ST
segment elevation . A data monitoring committee recom-
mended early termination of the trial during its second
interim data analysis after 50% of the anticipated sample size
had been entered . A preliminary report on 1,004 patients
revealed a 30 day mortality rate of 12.2% (61 of 502 deaths)
in the placebo group and 6.4% (32 of 502 deaths) in patients
assigned to APSAC (p = 0.0016). The overall mortality
reduction was 47%, with the patients entered between 4 and
6 h having nominally larger reduction than those entered at
<4 h (52% versus 41%, respectively) . The overall benefit of
therapy appears to persist and perhaps increase between the
30 day and I year follow-up evaluations . The estimated I
year mortality rate is 19 .4% and 10.8% in the placebo and
APSAC groups, respectively, a 44% reduction (p = 0 .0006) .
At this time, APSAC is a promising thrombolytic drug and it
joins streptokinase and rt-PA as a useful therapeutic alter-
native
. Again, direct comparisons between re-PA and
APSAC have not been made, but recently reported trials
(104-106) comparing streptokinase and APSAC show them
to be of equal efficacy, with APSAC showing a trend to
higher early patency and having an advantage in ease of
administration .
Thrombolytic therapy and fafarct site
. The two largest
trials, GISSI and ISIS-2, as well as many of the small trials,
have evaluated the efficacy of thrombolytic therapy relative
to the location of infarction
. This is important because it is
nearly always possible to predict the location of infarction as
being anterior, lateral, inferior or overlapping these areas
based on the location of ST segment elevation on the initial
ECG. It is much more difficult to distinguish the presence of
true posterior Q wave infarction in patients presenting with
anterior ST segment depression, but this location of infarc-
tion is infrequent
. It is now established by GISSI and other
trials that anterior infarction has the highest mortality rate
and benefits most from thrombolytic therapy ; the efficacy of
therapy in patients with inferior infarction is less clear .
Patients with inferior infarction did not have a significant
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reduction in the mortality rate in the GISSI trial, but did
benefit fs .)m streptokinase and aspirin therapy in ISIS-2 .
Likewise, patients with prior infarction did not benefit in the
GISSI trial, but did benefit in ISIS-2 . A recent publication
from GISSI (107) has demonstrated that the size of the
infarct as judged by the number of ECG leads with ST
elevation rather than location alone is predictive of benefit
from streptokinase therapy
. Many clinicians believe that
thrombolytic therapy is indicated in patients who are by-
potensive or are in cardiogenic shock, especially those who
have an evolving inferior infarction with associated right
ventricul^r ischemic dysfunction or infarction, or both . The
efficacy of thrombolytic therapy in these patients is not as
yet established .
Contraindications to thrombolytic therapy. The major
side effect of all thrombolytic agents is hemorrhage . The
contraindications to thrombolytic therapy include:
Absolute Contraindications
I
. Active internal bleeding .
2
. Suspected aortic dissection .
3
. Prolonged or traumatic cardiopulmonary resuscitation .
4 . Recent head trauma or known intracranial neoplasm .
5 . Diabetic hemorrhagic retinopathy or other hemorrhagic
ophthalmic condition.
6 . Pregnancy.
7
. Previous allergic reaction to the thrombolytic agent
(streptokinase or APSAC) .
8 . Recorded blood pressure >200/120 mm Hg
.
9. History of cerebrovascular accident known to be hemor-
rhagic.
Relative Contraindications*
1 . Recent trauma or surgery >2 weeks ; trauma or surgery
more recent than 2 weeks, which could be a source of
rebleeding, is an absolute contraindication .
2
. History of chronic severe hypertension with or without
drug therapy.
3. Active peptic ulcer.
4. History of cerebrovascular accident .
5. Known bleeding diathesis or current use of anticoagu-
lants .
6
. Significant liver dysfunction .
7
. Prior exposure to streptokinase or APSAC (this contrain-
dication is particularly important in the initial 6 to 9
month period after streptokinase or APSAC administra-
'These should be considered on a case by case analysis of nsk
versus
benefit, In instances where these contraindications (particularly I to 5) have
paramount importance, such as more recent trauma or surgery or active
peptic ulcer with history of
bleeding, they become absolute commindications
when weighed against a less than life-threatening, evolving acute myocardial
intention.
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tion and applies to reuse of any streptokinase-containing
agent, but does not apply tort-PA or urokinase).
Hemorrhagic complications
. The major nonreversible
complication of thrombolytic therapy is intracranial hemor-
rhage . With currently used doses of streptokinase (1.5 mil-
lion U over I h), the risk of intracranial hemorrhage has been
reported (8,9,108) as I to 10 per 1,000 patients treated . In
addition, gastrointestinal hemorrhage of varying severity can
be expected in 5% and genitourinary bleeding in a similar
number . However, most hemorrhagic complications in clin-
ical trials have occurred at the site of vascular invasion .
Venous and arterial puncture should be kept to an absolute
minimum in patients treated with thrombolytic agents and
should be
cared for meticulously thereafter .
Intracranial hemorrhage after rt-PA may be dose-related .
Estimated event rates with 150 mg are on the order of 15 to
20 per 1,000 and with a dose of 100 mg the rate is 5 to 10 per
1,000 (109). Intracranial hemorrhage after APSAC has not
been well defined
.
Thrombolylie therapy in older patients . Mortality and
case fatality rates with myocardial infarction increase
steeply with age. In fact, nearly 50% Tf all deaths in patients
hospitalized for acute infarction occur in those >75 years of
age (110). Trials of thrombolytic therapy, with the exception
of ISIS-2 and GISSI (which had no age exclusion), have
excluded patients >70 years (AIMS) or >75 years (ASSET,
European Cooperative Study) largely because of a fear of
hemorrhagic complications
. ISIS-2 reported a 16% reduction
in the 5 week vascular mortality rate (18
.2% versus 21 .6%) in
the streptokinase group >70 years of age at entry, a 26%
reduction (10.6% versus 14.4%) in the streptokinase group in
those 60 to 69 years and a 28% reduction (4 .2% versus 5.8%)
in the streptokinase group in <60 years . The GISSI trial
noted a 13% reduction in mortality at 3 weeks in those >75
years, an S% reduction in those 65 to 75 years and a 26%
reduction in those <_65 years
. The reduction in mortality did
not reach statistical significance in the two older categories
.
Risk of bleeding complications was not tabulated by age in
the ISIS-2 or GISSI reports. Given the attenuation of strep-
tokinase effect with increasing age reported in the ISIS-2 and
GISSI trials and the paucity of data on use of rt-PA and
APSAC in the elderly patient, the administration of throm-
bolytic therapy to older patients should be judicious with
careful screening for potential bleeding risk
.
Recommendations for Administration of
Thrombolytic Therapy to Patients With
Myocardial Infarction
Patients Without Contraindications to Thrombolytie Therapy
Class I
I . Patients <70 years of
age who present with chest pain
1ACC Y.I. It . an. t
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consistent with the dingncais of acute myocardial infarc-
lion and at least 0.I mV of ST segment elevation in at
least two contiguous ECG leads in whom treatment can
ho initiated
within
6 h of pain onset.
Class law
1 . Patients between 70 and 75 yews who present with chest
pain consistent with the diagnosis of acute myocardial
infarction and at least 11.1 mV of ST segment elevation in
at least two contiguous ECG leads in whom treatment can
be initiated
within 6 h of pain onset
.
2. Patients with acle myocardial infarction ?6 h after
symptom onset . but with a "statterine' pattern of pain .
3. Patients who slE'er clinically apparent reinfarction in the
days aRer administration of tlrombolytic therapy .
Clam Ilb
1
. Patients who present with chcst pain coaaiatent with the
diagnosis of acute irtyucardial itfaretiun and at least 0 .1
MY of ST segment elevation in at leant two contiguous
ECG leads in wham treatment can be initiated between 6
and
24 h after pain onset,
2 . Patients t-75 years of age who present with chest pain
consistent with the diagnosis of acme myocardial itd -arc-
tion and at least 0
.1 mV of ST segment elevation in at
Ieast two cantiguo
:ts ECG leads in whom treatment can
be initiated within 6 h of pain onset where the impending
infarction is COteasive-
3
. Patients who present with chair pain consistent with the
diagnosis of acute myocardial infarction with ECG changes
less profound than 0
.1 mV of ST segment elevation in Iwo
contiguous leads who can be treated within 24 h
.
CIMS Ill
Patients wla have had chest pain whew
1 . TYeatmenl caaaot be imttated wtthm24 h ut inset of chest
pair and pain has not rceurecd .
2_ Chest pain outset it unknown and has receded,
3. The cause of the chest pods is ancient,
Follow-Up Therapy After Theornhalysis
Very few data are available regarding management after
thrambotyti: therapy, Information regarding the effects of
rations therapeutic agents often used during the acute stage
of myocardial infarction (such as beta-blockers . aitruglyc-
erin and calcium channel bleckersl is based on findings from
randomizer clinicai trials that were carried out in patient
cohorts that did not receive thrombolytic therapy . The
question awes whether one can assume that if an agent was
beneficial in cliaicnl trials of myocardial infarction in the
absence of reperlusion, it would he similarly beneficial in
patisnla who have received thrombolytic treatment . There
ate theoretic reasons for believing that this may riot be the
case. Far example, randomized clinical trials of beta-
blockers given to patients in the early hours of a myocardial
infarction suggest that early mortality rates may be reduced-
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In cunirast, rarxknnized clinical trials compatitgeacima chat
.
reel blockers with placebo in cases with ST segment elevation
and transmural infarction bare lwwn tar bemft . However,
one could postulate that the opposite might he
the in the
patient who has had succesnM reperfusion
. Recanaliaonion
may enhance vase noler activity a the infarct-related artery
consequent to the liberation of vasoaeliee subslanees from
platelet aggregation. Under these circumstances, a calcium
channel blocker such as rifedipine that inhibits csrenety
vasospasrn might be preferable
to a beta-adrenergic receptor
blocking drug, which
theoretically
might result a enhanced
coronary vasospasm, reflecting unopposed otpha .adrcacrgie
activity. This is purely speculative
. but serves to empkavae
that only a srvai amount of randomized clinical trial data after
raperfusien are currently available .
Beta-Maker 0eipy
. The TI Hill trial (19T tattanirted
management alternatives in patients
after thrombulytic lber-
epy . One arm of that trial dealt with the specific question as
W the effect of bola-blackens, after thronddvsit. Patents
were randomized to receive a beta-bloeher immed steLy or at
the end of the first week of hospitalization
. Left aeatricalar
ejection fraction was the end point. No statistically
sigttlft.
cunt difference was demonstrated in the group randomized
to immediate intervention with a beta-blocks compared
withthose in whomaral administration was be" atappraK-
imately I week ; however, it sins noted that if beta-hlockers
were given within the first 4 h after hospitalizataar, a
significant improvement in the rate of ttoefatal reiniarclion
and recurrent ischemia was observed- Far patients with
illusions slanted within 2 In of syntptom onset, death or
recurrent myocardial infarction occurred significantly leas
frequently in those treated with Intravenous heta-blockade
179) . It thus seems reasonable to use seta-blocketa as one
might in the patient who has net mrderyone thrum iulysis
(that is, in patients who demonstrate increased adrenerglc
activity manifestedhy tachyeardia a hypertcesiyn in wham
beta-blackens are nor otherwise contraindcarri) Addition-
ally, patients demonstrating continuing ischema character
!zed by recurrent chest pain after thrombolnic therapy
presumably will benefit from administration of a bela-
blockcr, however, these patients are also candidates far
immediate study in the cardiac catheterizatior laboratory
with a view toward the performance of angioplasty orhypas s
graft surgery. Finally, if the patient develops atria) lirilla-
Lion with a fast ventrieulne response or develops reflex
tachycardia from the use of other agents suds as calcium
channel blockers or nitrates after thromholyrie therapy, a
beta-blocker may prove highly useful in stowing heart rate
Intravermusnitroglycoein . This is a highly effective agent
in the patient who has not received thrombolytic therapy,
and after tbrombolysis it appears to have the same rationale
for its use. The coronary vasodilating effects of nitrates and
their preload-reducing erects appear to justify their
rolling
se during the first day or two after thrombolytic therapy .
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Calcium channel blockers. Reocclnsion after recanaliza-
tion is a serious limitation to the benefits of thrombolysis .
Spasm has been proposed as playing a rote in promoting
recurrent occlusion after reperfusion
. Hyperreactivity of the
coronary vessels exists, as noted earlier, and the particular
effectiveness of calcium channel blockers in combating
spasm is well documented . A similar experience has been
observed in patients after angtoplasty . Therefore, although
spasm has not been proved as causative in early reocclusion,
calcium channel blockade has been suggested . Any of the
calcium channel blockers would seem suitable under these
circumstances, although the widest experience has been
gained with the use of nifedipine, which is the agent that
produces the greatest increase in sympathetic tone, and may
have to be combined with a beta-Mocker to offset the reflex
tachycardia
. Their use appears reasonable in patients with
preserved left ventricular function and coronary artery
spasm not responsive to the usual dose of nitrates .
Heparin and aspirin. One major effort directed to the
prevention of rethrombosis is the administration of intrave-
nous heparin . Some physicians begin heparin concomitant
with the start of the administration of rt-PA, whereas others
give heparin after completion of the rt-PA infusion or after
the usual 30 min to I h infusion of streptokinase . Heparin is
normally started in a dose of 600 to 800111th, often preceded
by a bolus injection of 5,000 111, with the dosage subse-
quently adjusted to maintain the active partial thromboplas-
tin time between 1 .5 and 2 times control values .
It is generally accepted that the usual pathophysiologic
basis of acute coronary occlusion leading to acute myocardial
infarction is plaque rupture with subsequent thrombus forma-
tion. Successful fibrinolysis restores patency of the lumen, but
the underlying vascular injury and residual thrombus persist
and have active surfaces
. For this reason, it is advisable that
patients receive both heparin and aspirin
. It must be appreci-
ated that the combination of heparin and aspirin may increase
the likelihood of a bleeding complication
. Low dose aspirin
may prove to be effective and the ISIS-2 data (10) indicate the
daily dose to be 160 mg . Over the next several days if the
patient has an uncomplicated course, heparin can be discon-
tinued, although aspirin should
be continued indefinitely . An
alternative strategy in those who cannot take aspirin is to
switch to coumadin before hospital discharge with the view
toward long-term oral anticoagulant therapy .
Recommendations for Follow-Up Therapy
After Thrombolysis
Class I
1
. Intravenous infusion of hepar .n over several days begun
with or after thrombolytic therapy
.
2 . A 160 mg aspirin tablet daily beginning immediately
.
3
. Intravenous or topical nitroglycerin for 24 to 48 h
.
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4. Early intravenous beta-blocker, followed by oral adminis-
tration if patient is hypertensive, demonstrates reflex taehy-
cardia, has atrial fibrillation with rapid ventricular response
or develops
postinfaretion angina, provided usual contrain-
dications to beta-blacker therapy are not present .
S. Early coronary arteriography if the patient develops
evidence of recurrent myocardial ischemia .
Class Ila
I. Early routine intravenous beta-blocker in patients with-
out contraindications .
2 . Calcium channel blocker while hospitalized to protect
against episodic coronary vasospasm, except in patients
with pulmonary congestion or left ventricular dysfunc-
tion .
Anticoagulants and Platelet Inhibitory Agents
The goals of antithromhotic therapy during and early after
acute myocardial infarction include 1) prevention of deep
venous thrombosis and pulmonary embolism, 2) prevention
of arterial embolization, 3) reduction of early recurrence or
extension of myocardial infarction and death, 4) reduction of
early reocclusion and death after successful reperfusion with
thromholytic therapy, and 5) secondary prevention of late
recurrence of myocardial infarction and death .
Prevention of Deep Venous Thrombosis and
Pulmonary Embolism
Introduction . As assessed by indium-125-labeled fibrin-
ogen, the incidence of deep venous thrombosis in the lower
limbs of patients with acute myocardial infarction ranges
from 17% to 38%, which is similar to the incidence in
patients after operation (I11). These observations and the
increased risk of recurrent myocardial infarction within 3
months of a previous infarction in patients undergoing non-
cardiac surgery may indicate a hypercoagulable state early
after acute myocardial infarction similar to that after major
surgery. Deep venous thrombi form early after the myocar-
dial infarction (a50% within 3 days), with an incidence that
is increased after massive or recurrent infarction with heart
failure or cardiogenic shock, prolonged immobilization and
certain characteristics, especially age >70 years (I It) .
Low dose heparin started within 12 to 18 h of the onset of
symptoms of acute myocardial infarction and continued for
10 days has successfully reduced the incidence of venous
thrombosis in three randomized trials (Ill) from a mean of
23% in 145 control patients to 4% in 138 treated patients .
This significant benefit is particularly apparent in high risk
subgroups that can be
identified within the first 24 to 48 h
(I11) . One small trial (111) of low dose heparin after myo-
cardial infarction showed no benefit, but the time of initia-
tion of therapy in relation to the onset of symptoms was
unclear
.
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Current Recommendations
Class I
l . Immediate subcutaneous heparin (5,000 U every 12 h) for
the first 24 to 48 h unless full dose anticoagulant therapy
has been initiated in association with thrombolylic ther-
apy or for the prevention of systemic emboli (vide infra) .
2
. Continued tow dose subcutaneous heparin in high risk
patients (age >70 )ears, large acute myocardial infarct
lion, previous myocardial infarction, heart failure or
shock, necessity for immobilization for >3 days . prior
deep venous thrombosis or pulmonary emboli, obesity or
evidence of chronic venous insufficiency) until fully am-
bulatory .
Prevention of Arterial Embolism
Introduction. The overall incidence of mural thrombus is
approximately 20% in acute myocardial infarction, approxi-
mately 40% in anterior myocardial infarction and approxi-
mately 60% in large anterior myocardial infarction . '-low-
ever, the incidence of clinically apparent systemic embolism
is only about 2%, 4% and 6%, respectively (112)
.
Based on three large prospective studies (I it-113) . the
incidence of left ventricular mural thrombus at postmortem
examination in patients who died after acute myocardial
infarction was 40% to 50% in patients not treated with
anticoagulants versus 22% to 24% in those treated with
anticoagulants (111,113). For the prevention of mural throm-
bus over a short period of 10 days (114), high dose subcuta-
neous heparin (12,500 U every 12 h) has recently been found
to be of significant benefit when compared with low dose
subcutaneous heparin (5,000 U every 12 h) . The overall
incidence of nonhemorrhagic stroke in this early period was
< 1% in those initially treated with high dose heparin and 4%
in the low dose group . Because of insufficient sample size
and low event rates, this difference did not reach statistical
significance. Patients treated with heparin and followed up
for up to I month with administration of oral anticoagulants
at relatively low doses (115) had a reduction in the incidence
of cerebral embolism from about 3% to 1% when compared
with no anticoagulant therapy (113). Anticoagulant therapy
has been effective if given on admission to the hospital; delay
until a mural thrombus is demonstrated echocardiographi-
cally may miss the time in which therapy can be most
valuable 1112) . Most systemic emboli occur within the first 2
to 3 months and particularly within the first 10 days . Accord-
ingly, a strategy of administering heparin, subcutaneously or
intravenously, in a dosage sufficient to prolong the activated
partial thromboplastin time to 1 .5 to 2
.0 times the control
value is advocated for patients with a large anteroapical
infarction, beginning immediately after the onset of infarc-
tion and continued for a period of about 10 days (116) . In
some patients (for example, those with ventricular mural
thrombus or large akinelic regions identified by ECG), it is
appropriate to continue with oral anticoagulants for approx-
imately 3 months. Warfarin should be used in dose sufficient
to prolong prothrombin time, using rabbit brain thrombo-
p
:astin to an internationally normalized ratio (INR) of 2.0 to
3.0, or 1 .3 to 1 .5 times control (115). The INR is defined as
the prothrombin time ratio result that would be obtained if
the World Health Organization primary international refer-
ence thromboplastin (IRP) was used to test the plasma
sample (116).
In patients with chronic left ventricular aneurysm but
preserved wall motion outside the zone of infarction, the
embolic risk appears considerably lower after 3 months and
routine long-term anticoagulation beyond 3 months may not
be justified (117). Conversely, in those patients with chronic
diffuse left ventricular dysfunction, continued oral anticoag-
ulant therapy beyond 3 months may be justified (118)
.
Current Recommendations
Class I
1 . Immediate high dose subcutaneous or intravenous hep-
arin in a dosage sufficient to prolong the activated partial
thromboplastin time to 1 .5 to 2
.0 times control in patients
with a large anterior transmural myocardial infarction .
Heparin should be continued until discharge.
2. Oral anticoagulants administered at a dose sufficient to
prolong the prothrombin time to 1 .3 to 1 .5 times the
control value (INR = 2.0 to 3.0) after heparin in patients
who have a ventricular mural thrombus or a large akinetic
region of the apex of the left ventricle
. Anticoagulant
therapy should be continued for at least 3 months .
Class Ila
1 . Long-term (indefinite) oral anticoagulant therapy in pa-
tients with a diffusely dilated and poorly contracting left
ventricle. (Prolong prothrombin time to 1 .3 to 1.5 times
the control value, or INR = 2 .0 to
3
.0.)
Class Ub
I . In patients with anterior myocardial infarction requiring
anticoagulation up to 3 months for the prevention of
systemic emboli, low dose aspirin (80 to 160 mg1day) to
prevent coronary events may be added to the anticoagu-
lants and then continued alone indefinitely.
Reduction of Early Recurrence or Extension of
Myocardial Infarction and Mortality in Patients
Not Receiving Thrombolytic Therapy
Introduction . Extension or recurrence of myocardial in-
farction ranges from 14% to 30% as recognized by a second-
ary increase in MB CK and is comparable with the incidence
of 17% found at necropsy (I11)
. Recurrence during hospital-
ization is more common in patients with a smaller infarct
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(lower plasma enzyme levels). More than half of the early
recurrences occur within 10 days and the remainder occur
within 14 to 18 days after the initial infarction . In >85% of
patients studied, the ECG site of early recurrent infarction
has been the same as the initial site . Thus, early recurrence
and extension of infarction are nearly synonymous (Ill).
There is evidence of frequent spontaneous reperfusion after
myocardial infarction and a known incidence of reocclusion
after reperfusion, particularly in patients with high grade
residual lesions
. The reason for reocclusion may be related
to the association of high grade residual stenosis or residual
thrombus providing a very thrombogenic surface, or both .
Anricoagulanrandaniiplarelettherapy . During and early
after hospitalization, can the early recurrence and extension
of infarction be prevented by short-term anticoagulant ther-
apy? In the late 1960s and early 1970s, three randomized,
controlled, prospective studies (113,119,120) using heparin
followed by low dose anticoagulant therapy (with the equiv-
alent of an INR = 2.0 to 3.0), for up to I month were
significant enough to assess its value . In regard to mortality
and reinfarction rates in these three studies, there was only
a trend to beneficial results in the patients who had under-
gone anticoagulant therapy (113,119). Chalmers et al . (119)
analyzed all of the reported, adequately designed, random-
ized trials of oral anticoagulants in acute infarction and found,
when case fatality ratios were pooled, the small differences in
mortality rate in each study became significant by simple
chi-square analysis : the overall reduction in mortality rate was
21%; the reduction in the incidence of reinfarction was about
30% (120) . It was suggested that all patients without specific
contraindications be given anticoagulants during hospitaliza-
tion for myocardial infarction (120) .
The role of platelet inhibitors in the reduction of the early
mortality rate and recurrence (extension) of myocardial
infarction was confirmed by the recently reported ISIS-2
study (10)
. The 5 week vascular mortality (mostly cardiac
mortality) rate was reduced by 23% with aspirin alone and
was reduced a further 19% when aspirin and streptokinase
were both given. Furthermore, aspirin alone reduced the
incidence of early recurrence of nonfatal reinfarction by
49%
. Thus, irrespective of whether or not thrombolytic
therapy is employed, the use of aspirin during the acute
phase of myocardial infarction appears to
be justified .
Current Recommendations
Class I
I . Short-term aspirin begun immediately and continued for
at least I month at a dose of 160 mg/day . After I month,
aspirin should be continued at a dose of 160 to 325
mg/day-
Clam
Ila
l . Heparin followed by oral anticoagulant therapy for at
least I month after infarction (prolong prothrombin time
to 1 .3 to 1 .5 times control value).
Reduction in Early Reocclusion and Mortality
After Successful Reperfusion With
Thrombolytic Therapy
Introduction. After thrombolysis, significant residual
thrombus contributes to the stenosis visualized at angiogra-
phy, and such a thrombotic surface also contributes to more
thrombogenicity and reocclusion . Recently, reocclusion af-
ter thrombolysis has been reported in 5% to 15% of patients
(121,122), rates that are lower than reported in previous
years, probably because of more aggressive postlysis an-
tithrombotic approaches .
The TIMI-I investigators (100) observed that after throm-
bolysis, reocclusion occurred despite continued heparin
infusion (activated partial thromboplastin time 1 .5 to 2 .0
times control value) for 7 to 10 days . Reocclusion was not
concentrated within the first few days, but rather occurred
throughout the hospitalization . However, in the recent study
from Johns Hopkins University (121), no reocclusion during
hospitalization occurred when therapy with heparin (activat-
ed partial thromboplastin time 2 .0 to 3 .0 times control value)
pins aspirin (325 mg/day) and calcium channel blockade were
used . Thus, the role of heparin in adequate dosage plus
aspirin appears important for the reduction of rocclusiun
after thrombolysis (122) .
Current Recommendations
Class I
I . Aspirin (160 mg/day) should be started as soon as the
patient is admitted and given daily until discharge from
the hospital, at which time it can be continued at a dose of
160 to 325 mg daily.
2 . Heparin should be administered together with or imme-
diately after thrombolysis to maintain the activated par-
tial thromboplastin time approximately 1 .5 to 2.0 times
the control value for 24 to 72 h .
Secondary Prevention of Late Recurrence of
Myocardial Infarction and Death
Introduction
. Ten large trials using platelet inhibitor
drugs in postmyocardial infarction patients, mostly within
the first 2 years, have been conducted . They invo:ved large
numbers of patients and were randomized, double blind and
placebo controlled. In eight of these trials, aspirin (at a dose
of 300 to 1,500 mg/day) was used alone or combined with
dipyridamole. The pooled analysis suggests a significant
reduction in the mortality and reinfarction rates (15% and
31%, respectively) in the aspirin group (123). In patients with
unstable angina, the beneficial effect of aspirin in reducing
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cardiac events continues for the subsequent 2 years, even
after the patient becomes stable (124) . Finally, in patients
with non-Q wave infarction, long-term treatment with aspi-
rin plus dipyridamole produced a 53% reduction in coronary
events (125) .
In regard to the use of long-term oral anticoagulants after
infarction,
an
International Anticoagulant Review Group
(126) attempted to overcome the problem of inadequate
numbers by pooling data from nine controlled trials . Using
the pooled data, the review group concluded that death after
myocardial infarction was reduced by 20% by use of long-
term anticoagulants and that the reinfarction rate was re-
duced by >30% (126).
Long-term anticoagulant therapy . In 1980, the Sixty
Plus Reinfarction Study (127) from The Netherlands revived
the issue of the value of long-term anticoagulant therapy,
this time >6 months after myocardial infarction. In six
centers, ambulant patients >60 years of age were studied; all
patients were receiving anticoagulant therapy for w6 months
after documented myocardial infarction ; the average follow-
up period was 6 years. Eligible patients were randomized to
continue on anticoagulant therapy or discontinue the antico-
agulant and substitute a placebo . There was a dramatic 55%
reduction in the incidence of fatal and nonfatal recurrent
myocardial infarction in the group that received an antico-
agulant
. The greater benefit of anticoagulants in this trial
might be related to the better control of the anticoagulant
therapy and the relative stability of the group of patients
studied 6 years after infarction. Moreover, in contrast to the
first 1 to 2 years after infarction, recurrent thrombotic events
rather than myocardial factors dictated the long-term prog-
nosis (high specificity for antithrombotic therapy)
. Despite
the impressive results reported in this study (127), it is
unlikely that clinicians will
be
enthusiastic about routine use
of long-term oral anticoagulation after myocardial infarction,
simply because the risk of hemorrhage is much higher with
anticoagulants than with aspirin, which may be of similar
benefit (128).
Current Recommendations
Class I
1. Aspirin (160 to 325 mg daily) if not associated with
significant side effects .
Class Ira
1. Oral anticoagulant therapy with warfarin (Prothrombin
time 1 .3 to 1 .5 times the control value, or INR = 2.0 to
3 .0) rather than aspirin for long-term prevention of recur-
rence of myocardial infarction .
Summary. Anticoagulation therapy using subcutaneous
low dose heparin is recommended for all patients with acute
myocardial infarction not receiving thrombolytic therapy .
GUNNAR ET AL.
	
273
ACCIARA TASK FORCE REPORT
This is begun on admission and discontinued at 48 h unless
the patient is not a candidate for or capable of early
ambulation
. Those patients with a large anterior infarction,
particularly involving the apex of the left ventricle, should be
given full dose heparin and switched to an oral anticoagulant
(warfarin) when need for invasive evaluation or therapy is no
longer contemplated . Oral anticoagulants should be contin.
ued for 3 months .
To prevent reocclusion after thrombolysis and for pre-
vention of early and late reinfarction, long-term aspirin
therapy should be given as a platelet inhibitor to all patients
who can tolerate it. However, in the subgroup of patients
with a large anterior myocardial infarction, warfarin may be
needed fortir prevention of systemic emboli and has benefit
for the prevention of early and late reinfarction . Thus, in this
subgroup of patients, it may be reasonable to postpone the
use of aspirin until anticoagulants are discontinued once the
risk of emboli has ceased.
Percutaneous Transluminal
Coronary Angioplasty
Introduction . The guidelines for the use of percutaneous
transluminal coronary angioplasty have been previous pub-
lished in an ACC/AHA Task Force Report (129) . That report
outlines the immediate and long-term effects of elective
angioplasty, its risks and contraindications, the selection of
patients and current indications for its use
. The present
report will elaborate on the indications for angioplasty
in
patients with acute infarction . The use of angioplasty alone
in evolving acute myocardial infarction will be considered
separately from the use of angioplasty as an adjunct to
thrombolytic therapy.
Primary coronary angioplasty . Along with the increasing
interest in thrombolystis for the treatment of acute myocar-
dial infarction, there has been interest in mechanical reper-
fusion by coronary angioplasty
. There have been a number
of reports (130-135) describing the use of angioplasty alone
in the treatment of acute myocardial infarction. These have
all been relatively small series and only one (134) has been
randomized in comparison with an alternative therapy
(streptokinase). These studies have generally reported a
beneficial effect on left ventricular function, bet there has
been no good large scale randomized study comparing this
form of treatment with either conventional supportive ther-
apy or the most effective forms of thrombolytic therapy
given early during acute infarction .
Percutaneous transluminal coronary angioplasty as the
primary treatment strategy suffers from the Seed to have
facilities and personnel for cardiac catheterization and a
physician qualified to perform angioplasty available at all
times . Because of this, intravenous thrombolyss has be-
come established as the first line of therapy in acute myo-
cardial infarction in suitable patients .
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With this background, angioplasty should be considered
as primary therapy in acute myocardial infarction only when
facilities are available for expeditious transfer to a cardiac
catheterization laboratory and where the personnel have the
technical expertise and experience in performing angioplasty
in this acute situation . Primary coronary angoplasty may
appropriately be considered when a hospitalized patient has
acute myocardial infarction, a patient presents within 4 h
after onset of symptoms to an institution where adequate
facilities and personnel are available or when thrombolytic
therapy is contraindicated. Patients presenting in cardio-
genic shock are a special group that may benefit from
emergency angioplasty (vide infra) .
Although intracoronary thrombolytic therapy is not usu-
ally as practical as primary therapy, the use of adjunctive
intracoronary thrombolytic therapy during or after an angio
.
plasty procedure may be appropriate when there is evidence
of residual thrombus in the artery . In this situation, a smaller
dose can be used than That used intravenously (such as
50,000 to 500,000 U of streptokinase or urokinase) . Using a
smaller dose, particularly < 100,000 U, has the advantage of
avoiding a systemic lyric effect, therefore minimizing bleed-
ing complications resulting from thrombolytic therapy
.
Recommendations for Primary Angioplasty of
Infarct-Related Artery Only
Clam I
I . Patients presenting within 6 h of onset of pain and who
meet the criteria for thrombolytis but in whom throm-
bolytic therapy is clearly contraindicated and only if
facilities and personnel are immediately available . This
recommendation is operative only when data indicate a
large amount of myocardium is at risk .
Class III
I . Intermittent continuous pain indicating the possibility of
"stuttering" infarction, especially if there are ECG
changes, but without clear indication for thrombolytic
therapy.
2. Within 18 h of acute infarction in patients developing
cardiogenic shock or pump failure.
3. Patients who have had previous coronary artery bypass
graft surgery in whom recent occlusion of a vein graft is
suspected .
Class Db
1
. Patients with known coronary anatomy in whom throm .
bolytic therapy is not contraindicated, but who develop
symptoms and ECG evidence of acute infarction in hos-
pital at a time when rapid access !o a catheterization
laboratory with personnel experienced in performing ex-
peditious angioplasty for acute myocardial infarction is
available (completion within I h) .
2. Patients in whom thrombolytic therapy is not contraindi-
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cated who present within 4 h of onset of symptoms of
acute infarction at a facility where rapid access to a
catheterization laboratory with personnel experienced in
performing expeditious angioplasty for acute myocardial
infarction is available (completion within I h) .
Class In
This category applies to patients with acute myocardial
infarction who do not fulfill the Class I or li criteria. For
example :
I . Patients with severe left main coronary artery disease
when instrumentation of a more distal occluded artery
may be hazardous.
2 . Patients in whom only a small area of myocardium is
involved, as evidenced by clinical data or previously
known coronary anatomy .
3 . Dilation of vessels other than the infarct-related artery
within the early hours of infarction. (This may not apply
to the patient in shock or pump failure
.)
Aogtoplasly after thrombolyte therapy . Immediate angio-
plasry.
Although intravenous thrombolysis offers the prom-
ise of early reperfusion in up to 75% of patients (136), more
complete reperfusion may be possible by performing angio .
plasty in those with a high grade residual stenosis of the
infarct-related artery and those who failed intravenous
thrombolysis. Three well-controlled, relatively large pro-
spective trials (79,136,137) have, however, cast doubt on the
utility of this strategy when applied early after thrombolytis
and in the absence of continued or recurrent ischemia . The
TAMI trial (136), European Cooperative Study (137) and
TIMI-IIA (79) trial of urgent angioplasty failed to demonstrate
a significant improvement in global or regional ventricular
function in patients undergoing emergency (immediate) angio-
plasty of infarct-related vessels with a residual stenosis after
administration of tissue plasminogen activator compared with
patients receiving intravenous tissue plasminogen activator
alone and undergoing elective angioplasty (TAME trial), de-
layed angioplasty (TIMI-IIA trial) or no angioplasty (European
Cooperative Study). The incidence of complications and death
associated with emergency angioplasty was significantly
greater in those undergoing emergency angioplasty after intra-
venous rt-PA than in those undergoing intravenous rt-PA
administration without emergency angioplasty in the summed
results of the three trials. It therefore appears that urgent
angioplasty of infarct-related vessels with a residual stenosis
after rt-PA therapy has no significant benefit, but does have a
significant increase in
risk. The failure of angioplasty immedi-
ately after thrmbolysis may be related to an increased risk of
hemorrhagic infarction when angioplasty is performed after
administration of tissue plasmi nogen activator or to an in-
creased risk of rethrombosis
. Thmbolytic agents such as
streptokinase, urokinase or tissue plasminogen activator have
been shown to cause platelet activation and release of throm-
boxane A2 (138,139).
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Because ihromholysis is incomplete 1.5 to 3 It after the
administration of an intravenous thrombolytic agent such as
tissue plasminogen activator, it is not surprising that angio-
plasty performed under these circumstances may further
predispose to platelet deposition an The residual thrombosis,
with subsequent, distal plateh.Ot embolization, reocclusion
and death
. Whether a similar risk exists with other throm-
bolytic ageos remains to be determined .
Delayed ongioplasty. In
view of the increased risk of
urgent angioplasty after thrombolysis, attention has focused
on the role of delayed and elective angioplasty . The need for
further revasculatization after intravenous thromholysis re-
lates to the often incomplete lhromholysis and the high
incidence of residual stenosis in the infarct-related artery
after intravenous thrombolysis . This is in part due to the
presence of residual thrombosis and in part to the underlying
atherosclerotic lesion . Patients undergoing thrombelysis
alone, such as in the GISSI trial (9) or the Western Wash-
ington trial
(96),
had a higher incidence of reocelusion and
reinfarction than those not given a thrombolytic agent
. The
significant advantages of early repetfusion in patients with
anterior myocardial infarction in the Western Washington
trial of intracoronary streptokinase were lost over a year
follow-up as a result of reocclusion of the infarct-related
artery and reinfarction. lna recent study. Mathey et al . 1140)
reported that patients undergoing coronary artery bypass
graft surgery after reperfusion with streptokinase had a
better survival rate than patients undergoing thrombolysis
alone .
The ISIS-2 study, in which aspirin was given in
conjunction with intravenous streptokinase . suggested a
reduced incidence of reinfurion compared with that from
intravenous streptokinase alone (10) . The benefieid result of
the u.,e of aspirin in conjunction with intravenous streptoki-
nase in regard 10 survival, reocclution and reinfairction may
modify
the
need far delayed angioplasty
. Nevertheless. a
high grade residual stenosis with die potential for recurrent
ischemia and infarction persists in many patients after intra-
venous ehrombolysis, suggesting a potential role for delayed
or elective angioplasty .
In the Jahns Hopkins University trial (121) of delayed
angioplasty, patients were first randomized to receive tissue
plasminoggen activator or placebo and then after 49 to 72 h
were rerandomized to undergo or not undergo angioplasty
.
At follow-up study before hospital discharge, patients under-
going angioplasty had a significant improvement in exercise
ejection fraction but not rest left ventricular ejection fraction
compared wills those not undergoing engic plasty . The risk of
angioplasty under these circumstances 48 to 72 h after
infarction does not appear to
be appreciablygrester than that
for elective angioplasty . The advantages of this strategy
include avoiding the risk of early angiography, avoiding the
risk of emergency angioplasty and achievinga high incidence
of final reperfusion . a decrease in the incidence of recurrent
ischemic events and an improvement in exercise-stressed
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ventricular function. A disadvantage of this strategy is the
possible overuse of angioplasty in low risk individuals .
The TIMI-11B
investigators (79) examined the strategy
of
delayed angioplasty in a relatively large number of patients
and demonstrated that there was no advantage of this strategy
on rest left ventricular ejection fraction or survival compared
with a nonnvasive strategy in which angioplasty was per-
formed only for postinfarction angina or the development of
ischeieia on stress testing before hospital discharge (79}
.
The
noninvasive strategy avoids the risk f
early
antgiography and
urgent angioplasty. It restricts the use of coronary augioplasty
to those at increased risk o f ischemic events
. The disadvantage
of this strategy relates to the failure to identify coronary
anatomy and the argument that a submaximel prehospitat
discharge stress test may not reliably predict recurrent ische-
mic events, roinfarction and dealt .
In view of the failure of available data to demonstrate an
advantage of salvage or rescue angioplasty and the failure to
show a benefit of routine urgent or delayed angioplasty after
successful thrombolysis, it appears that an elective or Ron-
invasive strategy is preferred . Until further data arc avail-
able from prospective controlled trials, a conservative ap •
proach after intravenous thrombolylic therapy seems
indicated . This would reserve angiography and angioplasty
for patients with postiofarction angina, severe left ve neicu-
lar dysfunction or stress-induced myocardial ischemia de-
tected before hospital discharge .
Recommendations for Angioplasty After
Intravenous Thrombolysis
Class I
Dilation of a significant lesion suitable for Coronary antic,
plasty in the infarct-related artery in patients who arc in the
low risk group
for
angiograpbic-related morbidity and mor
,
ttdity who have a type A lesion (see ACCJAHA Task Furor
Report en coronary angioplasty [1291) and;
I . Have recurrent episodes of ischemfc chest pain pmticularb
if accompanied by FCG changes (postkafatclion Begun).
2 . Show evidence of myocardial iscliemia while on aptimil
medical therapy during submaxinlal stress testing per
formed before hospital discharge or
on maximal sires!
testing in the early posthospital period
.
3. Have recurrent ventricular mchycardia or vemricula
fibrillation, or both, convincingly related to ischemir
while on antiarrhythmie therapy .
Claus Hn
Dilation of significant lesions In patients who
:
1 . Are similar
to those in class I but who have type B lesiom
(anticipated success rate 60% to 85%) (sec ACC1AHA
Task Farce Report on
coronary angioplasty 1129)).
2. Are within
18
h
of onset of acute infarction and have
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cardiogenic shock or pump failure . These patients should
be studied and undergo reperfusion as soon as possible .
3. Before hospital discharge in those who have survived
cardiogenic shock or pump failure .
Class Ilb
Dilation of a lesion in patients who:
1 . Have an occluded coronary artery after attempted throm-
bolyric therapy .
2. Require multivessel angioplasty
.
3
. Have >90% diameter proximal narrowing of an infarct-
related artery with a large area of viable myocardium still
at risk.
Class in
All patients in the immediate postinfarct period (during
initial hospitalization) who do not fulfill Class I or II criteria .
For example:
1
. Dilation in patients who are within the early hours of an
evolving myocardial infarction and have <50% residual
stenosis of the infarct-related artery after receiving a
thrombotytic agent
.
2 . Dilation of lesions in vessels other than the infarct-related
artery within the early hours of infarction .
3
. Dilation of residual lesions that are borderline in severity
(50% to 70% diameter narrowing) of the infarct-related
artery without demonstration of ischemia on functional
testing.
4
. Dilation of type C lesions (see ACC/AHA Task Force
Report on coronary angioplasty for definition [1291)
.
5 . Undertaking angioplasty in patients in the high risk group
for morbidity and mortality (see ACC/AHA Task Force
Report on coronary angioplasty for definition 1129)) .
Pump Failure and Shock in Acute
Myocardial Infarction and Use of Intraaortic
Balloon Counterpulsation and Other
Circulatory Assist Devices
Pump failure and shock represent a clinical spectrum
more easily defined than treated . The clinical syndrome
includes a weak pulse, poor peripheral perfusion with cool
cyanotic limbs, obtundation and oliguria . Blood pressure
taken by cuff is usually low and there are variable degrees of
pulmonary congestion . The heart sounds are usually quiet
and a third heart sound may have a variable degree of
prominence. Because the best treatment is prevention, re-
lieving the load on the left ventricle and improving the
myocardial oxygen supply/demand ratio in patients showing
early evidence of hemodynamic deterioration should be
vigorously undertaken . It is most probable that the current
use of hemodynamic monitoring and early use of afterload-
reducing and oxygen-sparing agents are the reason we see
the shock syndrome less frequently than in the past (141) .
Before defining the various subsets of pump failure, we
must be certain that the filling pressure of the ventricle is
JACC Vol. 16, No
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adequate
. There are several reasons for volume depletion in
patients with acute myocardial infarction, including overvig-
orous diuresis, volume loss through the gastrointestinal tract
at the onset of the syndrome, use of pressor agents and a
period of cardiac arrest during which intravascular volume
may be diverted into the third space (34,142) . If the filling
pressure of the left ventricle is <15 mm Hg, it is hard to define
pump failure, and before more active intervention, it is useful
to challenge intravascular volume sufficiently to bring the filling
pressure of the left ventricle to 18 mm Hg . This must be done
as a challenge infusion over a short period of time because
prolonged infusion can lead to pulmonary congestion without
elevation of left ventricular filling pressure .
The treatment of pump failure should be divided accord-
ing to hemodynamic subsets and patients may move from
one subset to another, requiring change in the therapeutic
regimen (17).
Subset 1 . Left ventricular filling pressure >15 mm Hg,
systolic arterial pressure >100 mm Hg and
cardiac Index <2 .511ters/min per ma . This sub-
set has left ventricular failure ; the arterial pres-
sure is sufficiently high to allow for afterload
reduction as the first line of therapy (143). It is
a subset that, within itself, has a spectrum from
hypertension and pulmonary edema to systolic
pressures approaching 100 mm Hg, less prom-
inent pulmonary congestion and more marked
evidence of peripheral hypoperfusion . The two
vasodilator agents most commonly used are
nitroprusside and nitroglycerin. Nitroprusside
has the benefit of more active afterload reduc-
tion (144)
. Nitroglycerin has a greater degree of
venodilator effect and also relieves ischemia by
dilating epicardial coronary arteries. When
ischemia is not prominent and the epicardial
coronary artery dilator effect of nitroglycerin is
not needed, nitroprusside becomes the agent of
choice . Conversely, in the early hours of acute
infarction when ischemia plays a prominent
role in ventricular dysfunction, nitroglycerin
may be the more appropriate agent. When
using nitroprusside, the patient should be mon-
itored for arterial and left ventricular filling
pressures. The initial dose should not exceed
10 pg/min and increase by 5 pg/min every 10
min. If cardiac output increases and the shock
syndrome abates, the infusion should be con-
tinued . If arterial pressure decreases, tachycar-
dia develops or the cardiac output increase is
insufficient, or both, one should add dobu-
tamine beginning at 5 pg/kg per min and in-
crease the dose to a maximum of 15 pg/kg per
min (145). Intravenous amrinone with its va-
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sodilating and inotropic effects can also be
considered . If arterial pressure decreases more
precipitously, dopamine should be substituted
for dobutamine. Throughout this period of
treatment, use of the intraaortic balloon pump
for counterpulsation should be considered be-
cause it is the only treatment that increases
coronary blood flow and simultaneously re-
duces work for the left ventricle . Even in the
patient with hypertension who is in pulmonary
edema, the balloon pump will tend to tower
arterial pressure by its inherent vasodilating
effect through double bombardment of the
baroreceptors . As one stabilizes the patient
with this syndrome, gentle use of diuretic drugs
may be indicated if pulmonary congestion con-
tinues to be a problem . Pulmonary congestion
can ofrn be monitored better by measurement
of blood gasses combined with changes in
wedge pressure than by appearance of roles .
Subset 2. Arterial pressure <90 mm Hg, left ventricular
filling pressure >15 mm Hg and cardiac output
<2.5liters/min per m2. This subset defines the
classic hypotensive shock patient with acute
myocardial infarction who has a 20% prognosis
for survival. It should be obvious to the reader
that we have excluded the patient with systolic
pressure between 90 and 100 mm Hg to allow
for clinical judgment as to whether the patient
is moving toward subset 2 or subset I and the
design of therapy on that clinical assessment .
Once the patient is defined to be in this subset
of pump failure, the balloon pump team should
be mobilized and the catheterization laboratory
should be prepared to accept the patient . If the
patient is markedly hypotensive, norepineph-
rine is the agent of choice until systolic arterial
pressure is brought in the range of 80 to 90 mm
Hg (146). At that point, a switch to dopamine
should be attempted. If the pressure is in the
range of 70 to 90 mm Hg, dopamine can be the
initial agent, beginning with doses from 5 to 15
pg/kg per min (147). When 20 to 30 Jrgikg per
min is exceeded to maintain arterial pressure .
the major effect of the agent is peripheral
alpha-adrenergic stimulation and administra-
tion of norepinephrine, which has less chrono-
tropic effect, is better. If the patient can be
stabilized so that arterial pressure is no longer
the problem, the best agent is dobutamine and
this can be given simultaneously with the
dopamine in the attempt to reduce the dopa-
mine requirement . However, dobutamine is not
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an agent to be used alone in the severely
hypotensive patient.
Subset 3. Right vralrleulor bdrction, elevated right *kW
and right ventricular dimtolc
l
(>10
now Hg), cardiac Idea <2.5 ihera/du per ma,
systolic premrre <100 amr Hg and left veatrie-
alar Big pressure normal or elevated. These
patients are important to recognize because
they are very sensitive to volume depletion and
frequently respond to volume infusion
. They
usually, but not always, have inferior wall
infarction. There may be varying degrees of left
ventricular dysfunction . The principles of ther-
apy differ from these for subset 2 in that right
ventricular filling pressure must be increased
by rapid administration of fluids unfit blood
pressure is stabilized, left ventricular filling
pressure is >20 mm Hg or right atrial pressure
is >20 nun Hg. Venodilator agents (such as
nitroglycerin) and diuretic drugs (such as furs
semide) should be avoided and dobutamine is
much preferred to dopamine because the latter
tends to increase pulmonary vascular resis-
tance. If volume replacement and mild intro
.
pie support is insufficient, it is useful to know
that these patients do respond to intraaortic
balloon counterpulsation and represent a group
of patients who, with appropriate therapy (in-
cluding counterpulsation if necessary), can be
discharged in New York Heart Association
functional class 1 (148). Right ventricular in-
farction must be differentiated from cardiac
tamponade, which is sometimes hemodynami-
cally simi ar.
All of these patients with pump failure, particularly if
seen in the first 12 or 24 h, deserve immediate transfer to a
facility equipped for catheterization, angioplasty and cardio-
vascular surgery. Angioplasty performed in the patient in
shock seen within the first 18 h of symptom onset has
resulted in a survival rate in the range of 50%, a marked
improvement over any reports using phmmacologic agents
and counterpulsation (149) . It is also important to define the
anatomic and physiologic abnormalities . Occasionally, se-
vere mitral insufficiency even without a murmur is present in
these patients. If global left ventricular dysfunction is due to
ischemia, reperfusion is important for the salvage of myo-
cardium. If it appears that the dysfunction is due to irrevers-
t71e myocardial damage, the patient may be a candidate for
heart transplantation, and if so, a left
ventricular
assist
device or mechanical heart implantation should be consid-
ered in centers so equipped (150). It must be emphasized
again that patients with pump failure or shock need to be
studied angiographically early so that intervention with
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angioplasty or surgery can be undertaken at a time early
enough to reverse hemodynamic deterioration .
Recommendations for Intraaortic Balloon
Counterpulsation or Other Circulatory
Assist Devices
Class I
I . Cardiogenic shock or pump failure not responding
promptly to pharmacologic therapy.
2
. Right ventricular infarction with pump failure or shock
not responding to volume infusion and appropriate phar-
macologic therapy.
3. Refractory postinfaretion angina for stabilization before
and during angiography.
4. Intractable recurrent tachycardia in patients with hemo-
dynamic instability during the arrhythmia (151).
Claw
lie
I
. Ventricular septal rupture.
2. Acute mitral insufficiency .
3. Persistent ischemic pain.
4. Progressive congestive heart failure despite pharmaco-
logic therapy, particularly as a bridge to more definitive
therapy .
Clan 111
1 . A patient who is reasonably stable and in whom balloon
insertion may delay more definitive therapy .
2. Severe peripheral vascular disease and fewer indications
than in Class 1 .
Surgical Intervention in Acute
Myocardial Infarction
Introduction. Guidelines for the surgical interventior.s
associated with acute myocardial iafarcton follow the indi-
cations as classified elsewhere ht this report. In addition,
surgical intervention may be grouped chronologically as
emergency (immediate, on mobilization at appropriate team
members and facilities, and within 4 h); urgent (within 24 h);
and elective (an interval of several days to several weeks) .
Cardiac arrhythmias
. There are no class I emergency
indications for surgery in this subset
of patients . Emergency
introduction of the intraaortic balloon pump for cardiac
arrhythmias that are incessant or produce hypotension has
been helpful in some instances (151)
. In patients with aneu-
rysmal expansion of the infarction associated with persistent
ventricular tachycardia and failure
of medical therapy, sur-
gical resection of the aneurysm and endocardial scar incision
along with coronary artery bypass grafting has been success-
ful (152)
. In general, intraoperative mapping, revasculariza-
lion and surgical ablation of reentry areae are reserved as
elective procedures and are indicated only if drug therapy
has failed. The surgical mortality rate is 107, to 209. and the
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freedom from recurrent arrhythmias and sudden death has
been reported to be 75% (153,154) .
Failed percrdaneous transluminal coronary angioplasty.
Coronary artery bypass grafting may occasionally be per-
formed as an emergency procedures. a patient with acwc
myocardial infarction and persistent pain or hemodynamic
instability after failed percutaneous transluminal coronary
angioplasty. Surgical intervention within 4 h (optimally 2 h)
can often lead to patient survival and minimal loss of
ventricular function (155)
. Survival varies with the severity
of the pump failure, urgency of the operative procedure and
skill of the operative team. Brahos et al. (156) report a 4 .4%
and 3.1% mortality rate for urgent and elective groups.
The most common urgent or elective surgical intervention
after failed coronary angioplasty is in the presence of a
closed vessel with new or persistent symptoms of ischemia .
Golding et al
. (157) reported two deaths in 81 patients
requiring surgery within 24 h after angioplasty
. There were
75 major complications in 52 patients . Reul et al . (158)
reported an overall surgical mortality rate of 3 .3% in 184
patients I week to 19 months after angioplasty, with one
death in 57 patients who were unstable
.
Postthrombolytic therapy
. In the patient who has re-
ceived thrombolytic therapy, there are no indications for
emergency surgical revascularization. Urgent operation in
patients not suitable for angioplasty is indicated for persist.
ing pain or evolving infarction despite thrombolylic therapy.
Skinner et al, (159) reported a 17% mortality rate and blood
use of 8
.2 Ulpatient in 24 such cases .
Elective surgical intervention after thrombolytic therapy
is indicated in patients with persisting symptoms and closed
or stenotic coronary arteries not suitable for angioplasty .
Additionally, elective coronary artery bypass graft surgery
must be considered in those patients with other elective
indications for cardiac surgery (160) . These indications in-
clude a markedly positive exercise test, a correctable me-
chanical derangement, left main coronary artery disease and
three or two vessel coronary artery disease not better treated
with angioplasty (161).
Recurrent inehemla . Urgent operation should be consid-
ered indicated when there are ST-T wave changes with pain
after and during the sate hospitalization as the initial
myocardial infarction, presuming the coronary anatomy in
this type of patient is not amenable to angioplasty . The
results of urgent revascularization in this group of patients
are highly correlated with ejection fraction . In those patients
with an ejection fraction >50%, survival is nearly equal to
that of elective revascularization . With increasingly de-
pressed left ventricular function, survival after urgent surgi-
cal revascularization is somewhat less but very similar to
that of elective bypass surgery in patients with depressed
ventricular function (162,163) .
Surgery far evolving myocardial tnfarNbn . Emergency
operation (within 6 h) for evolving infarction has been
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evaluated by Phillips et al. (155)
. DeWood et al
. (164) and
Flameng et al . (165). In each report, surgical treatment
appeared to improve survival or result in better salvage of
myocardium, or both, than occurred in matched retrospec-
tive control groups. However, surgical reperfusion is avail-
able less quickly in the evolution of infarction than is
thrombolysis or angioplasty . Therefore, except in those
communities where this has been established, emergency
bypass is not indicated until future studies show that this
approach is superior to thrombolysis and coronary angio-
plasty
.
Non.Q wave infarction
. Although DeWood et al . (164)
have shown improved survival in a nonrandomized group of
patients with non-Q wave infarction treated by emergency
bypass surgery as compared with conventional medical
treatment, emergency operation in this group of patients is
controversial . Urgent operation may be indicated in patients
with unstable rhythms, unstable angina
. unstable ECG
changes, pulmonary venous hypertension or significant left
main coronary artery disease . At particular risk are those
patients with transient ECG changes and postinfaretion
angina . This, in practicality, defines patients with two or
three vessel coronary artery disease not ordinarily treated
with coronary angioplasty who have persisting symptoms or
are developing congestive heart failure .
Elective operation in those patients who have had a
nod-Q wave infarction is indicated if there is left main or
three vessel disease, two vessel disease where the proximal
left ante, for coronary artery is significantly narrowed or with
two vessel disease and ejection fraction <dn% . 1 ;1 these
patients, elective surgery would be expected to prolong
survival (161,165,166)
.
Mechanical deraogements after myocardial infarction
.
Papillary muscle rupture producing acute mitral incompe-
tence is an
infrequent but catastrophic complication of
myocardial infarction. Emergency coronary artery bypass
graft surgery and mitral valve replacement are indicated .
Tepe and Edmunds (167) reported 5 survivors of 11 such
patients operated on within I month of myocardial infaterton .
Severe mitral insufficiency due to papillary muscle dys-
function or chordal rupture should be treated with intraaortic
balloon counterpulsation or afterload reduction, or both .
Surgery can be urgent, elective or not needed, depending on
the hemodynamic consequences, although with chordal or
papillary muse,: rupture, surgery will almost always be
indicated. Coronary artery bypass graft surgery and mitral
valve repair or replacement are indicated (168) .
Ventricular free wall rupture presenting as pseudoaneu-
rysm should be treated as an emergency unless it is discov-
ered late in the clinical course, in which case it should be
treated urgently. Surgical intervention consists of revascu-
larization, aoeurysmectomy and closure of the ventricular
defect (169)
.
Ventricular septal rupture with resulting left to right
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shunt, pulmonary venous and pulmonary arterial hyperten-
sion and low cardiac output is often life-threatening and is an
indication for operation
. It should be treated as an emer-
gency if pulmonary congestion, congestive heart failure or
pulmonary edema occur or there are manifestations of
cardiogenic shock. Urgent operation is indicated in the
absence of conditions as just stipulated . However, there is
emerging information (179) that emergency operation rather
than urgent or elective intervention is appropriate for ven-
tricular septet rupture even if the patient is stable and
particularly if the diagnosis is made early in the course of
infarction . The initial smaller rupture may be predictive of
more severe seplal or
free wall rupture .
Left ventricular aneurysm,
defined as a demarcated dias-
tolic deformity of the left ventricle appearing on left ventric-
ular angiography with systolic dyskinesia, may be associated
with congestive heart failure or important ventricular ar-
rhythmias . There are no emergency indications for opera-
tion . Urgent operation may be required when left ventricular
aneurysm is associated with intractable ventricular tachycar-
dia or intractable heart failure (151)
. The operative mortality
rate may be 6% to 15%. Operation can lake the form of
map-directed ventricular tachycardia surgery, left ventricu-
lar aneurysm resection, mitral valve repair or replacement
and coronary revascularization-The indication foropetation
in left ventricular aneurysm is the presence of intractable
congestive heart failure, ventricular tachyarrhythmias not
responsive to drug therapy and embolization desrite antico-
agulant therapy . In 1,131 patients reported from tie Coro-
nary Artery Surgery Study (CASS) Registry (ill), the sur-
gical mortality rate was 7 .9%. However, surgical priority
(emergency and urgent) was a significant operative risk
factor (171). Cardiac transplantation may be appropriate for
this and other mechanical derangements when ventricular
function is poor or after failure of conventional operative
approaches .
Pump Whim and audiogdic shock . In this situation
emergency intraaortic balloon counterpulsatio n and coro-
nary artery bypass surgery have led toe better survival rate
and greater salvage of myocardium than has treatment by
conventional pharmacologic means (172), but should be
deferred to angioplasty where feasible.
Recommendations for Surgery in the Early
Management ofMyocardial Infarction
Recmnmendaboas far Emergency or Urgent Caroavy
Bypass Surgery
rim I
I . Failed angioplasty with persistent pain or hemodynamic
instability.
2 . Postinl'arct angina with left main or three vessel disease
or where coronary angioplasty is not indicated, with two
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vessel disease involving the proximal left anterior de-
scending coronary artery or two vessel disease and poor
left ventricular function .
Class IIa
1
. At the time of surgical repair of ventricular septa) defect
or acute mitral insufficiency .
2
. Cardiogenic shock not suitable for angioplasty .
Class III
1 .
Where the available surgical mortality rate exceeds the
mortality rate associated with appropriate medical ther-
apy.
Recommendations for Emergency or Urgent
Cardiac Repair
Class I
1 . Papillary muscle rupture (emergency) .
2 . Ventricular septal defect or free wall rupture (urgent)
.
3 . Aneurysmal infarction with intractable ventricular ar-
rhythmias or pump failure (urgent), or troth
.
4. Acute mitral insufficiency with intractable failure (ur-
gent) .
5. Intractable ventricular tachycardia (urgent).
Class Hit
1 . Ventricular septa) defect or free wall rupture (emergen-
cy).
2. Severe mitral insufficiency with controlled failure (ur-
gent) .
Class III
1. Acute infarctectomy in hemodynamically stable patients
.
2
. Surgery where the operative mortality rate exceeds the
expected mortality rate associated with conservative
therapy.
Recommendations for Implantable Ventricular Assist Devices
Class I
None .
Class Ills
1 . As a bridge in a patient who has intractable pump failure
and who would be a reasonable candidate for cardiac
lmnspl,%ntation .
Predischarge Evaluation in Acute
Myocardial Infarction
Patients with acute myocardial infarction require serial
evatuatioe by their managing physician
. These daily clinical
assessments are usually combined with various diagnostic
studies performed during recovery or just before discharge .
Such an evaluation will allow the division of patients into
high and low risk groups and aid in choosing patients who
will benefit from myocardial revascularization in addition to
risk factor management and anti'schemic, antiarrhythmic or
antifailure therapy as appropriate (173)
. The prognosis after
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acute myocardial infarction is most directly related to the
extent of left ventricular dysfunction, the presence of resid-
ual myocardial ischemia and the degree of electrical insta-
bility of the myocardium (173-179). Many of the techniques
that can be used to define these factors are duplicative and
the clinician must choose those that are cost-effective, most
accurate in his or her own environment and will lead to
clinical decisions that can modify outcome or at least make
a major impact on prognostication .
Clinical assessment. There are certain clinical attributes
already present on admission that yield prognostic informa-
tion . By clinical assessment one can identify patients at high
risk who should have angiography before discharge and thus
may not need additional high technology assessment. Inf-
arct-related mortality increases with age (180), approaching
50% in patients >80 years of age (181) . A history of prior
acute myocardial infarction or chronic angina pectoris is
associated with an increased acute mortality rate and a
doubling of the mortality rate in the first 2 years after
infarction (174,182) . Although men have a higher incidence
of acute myocardial infarction, women have a poor progno-
sis (183). A history of hypertension increases the late mor-
tality rate for several years after infarction (182). Diabetes
mellitus increases the mortality rate by three- to fourfold
(184)
. Cigarette smoking is associated with an increased risk
of death in those who continue to smoke (182)
. One study
(185) of 818 patients described an index based on clinical
information available in the first 24 h (including maximal
blood-urea-nitrogen, history of prior myocardial infarction,
age, displaced left ventricular apex on physical examination
and bradycardia) to be strongly predictive of subsequent
death in the year after discharge .
Other predictive characteristics become apparent as the
infarction evolves. Anterior infarcts canny a higher short-
and long-term mortality rate than do inferior infarcts (171),
even when corrected for infarct size (186)
. Non-Q wave
infarctions have an initial mortality rate about half of that of
Q wave infarctions, but an increased incidence of late
extension and reinfarction and a compare e mortality rate
at 1 year (187) . An estimate of infarct size by analysis of CK
or MB CK release has significant prognostic information
(188) . The presence of congestive heart failure correlates
roughly with infarct size and bitimnte prognosis (60,182,189) .
Certain atrial arrhythmias (especially atria) fibrillation) ap-
pearing after the first 48 h are associated with left ventricular
failure and an increased risk of death (182) . Runs of three or
more consecutive premature ventricular complexes are in-
dependent predictors of early death (177) . Postinfarction
angina predicts nonfatal reinfarction in the following year
(190). Rest ST segment depression that persists denotes an
increased 1 year mortality rate .
The clinical characteristics just described identify a num-
ber of patients at increased risk before a formal predischarge
risk assessment . Patients with a complicated clinical course
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manifested by significant congestive heart failure (Killip
class III or IV), hypotension, ongoing ischemia, malignant
arrhythmia or suspicion of a mechanical defect are generally
candidates for cardiac catheterization without further extern
sive noninvasive evaluation
. Approximately 60% to 80% of
all patients who survive their first infarct to leave the
hospital will be free of these indications by the fifth postin-
farction day (179,191). These relatively uncomplicated pa-
tients can be further stratified into high and low risk sub-
groups by the application of the following technologies
.
Exercise Wing. The role of exercise testing in evaluating
patients after acute myocardial infarction has been exten-
sively discussed in a prior ACC/AHA guideline report (191) .
The risk of symptom-limited exercise testing is low in
properly selected patients at 10 to 14 days after infarction . In
predischarge testing at 6 to 10 days after infarction . how-
ever, a submaximal test should be used
. Five METS is a
useful end point in the absence of limiting symptoms such as
angina, dyspnea or fatigue . However, arbitrary limits of 120
to 130 beats/min or 70% of maximal predicted heart rate for
age have been used to establish the safety of early exercise
testing. Safety is likewise maximized when three or more
consecutive premature ventricular c
omplexes. S
T
segment
depression >2 mm or development of exertional hypoten-
sion to below baseline are taken as indications for termina-
tion of exercise.
Patients who have ST segment depression > I mm during
exercise have a 3 to 20 times higher risk of subsequent
cardiac events
. The I year mortality rate in this group is as
high at 15% (179). Patients able to achieve a high peak work
load generally have less ischemia and left ventricular dys-
function than patients capable of only low work loads
.
Inability to achieve a treadmill work load of 4 METS on
symptom-limited exercise testing 3 weeks after infarction is
associated with a sixfold increase in the risk of cardiac
death, nonfatal ventricular fibrillation or recurrent infarction
in the subsequent 12 months (192) . Inability to achieve a
peak systolic pressure of ?110 mm Hg, increase systolic
pressure by 10 mm Hg over baseline values or decrease
systolic pressure below baseline values also imply a poor
prognosis (193). In contrast, exertional hypotension (a de-
crease >10 nun Hg from the highest value achieved during
earlier exercise) occurring on the predischarge exercise test
is a relatively common and nonspecific finding and usually
does not warrant further immediate investigation. Many of
these patients will have more normal blood pressure and
heart rate responses on follow-up exercise testing 4 to 7
weeks later (194) .
The best time to perform the exercise test varies, depend-
ing on physician preferences, patient characteristics and
local laboratory expertise . There are strong arguments (193-
195) that symptom-limited maximal exercise testing at 3
weeks after myocardial infarction is a cost-effective alterna-
tive to submaximal predischarge testing at 10 to 14 days and
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can be used for prognostication as well as evaluation of
functional capacity . Because the trend to earlier discharge
decreases the hospital stay for an uncomplicated infarction
patient to e6 to 10 days, the safety of predischarge testing is
less well established . Symptom-limited testing at 3 weeks,
however. is proved to be safe and the delay seems to be
associated with very few instances of intercurrent death or
reinfarction in properly selected patients (195) . Patients have
a negative ECG response to w6 METS work load at 3 weeks
have a I year mortality rate of c2% (179,191,192,1%)
.
When a patient has difficulty in returning for exercise
testing, either because of transportation considerations, in-
adequate compliance or other causes of uncertain follow-up,
predischarge submaximal testing may be
preferred. In addi-
tion
. all patients who have had thrombolytic therapy should
have an exercise test before discharge
. The addition of
thallium-201 imaging or radionuclide ventriculogrxphy im-
proves the predictive oplue of the submaximal predischarge
exercise test (197) and may be
considered if locally available .
A second treadmill exercise test performed to symptom
limitation at 4 to 8 weeks may be necessary if clearance is
required before returning to work or restoring strenuous
leisure activities .
In uncomplicated patients being discharged at 10 to 14
days and properly selected as clinically at low risk, a
symptom-limited exercise test with a thallium-201 perfusion
scan or radionuclide ventriculogram can identify most
of the
patients in that group who are still at risk and therefore need
angiagmphy.
If a patient is selected for earlier discharge at 6 to 10 days,
a heart rate or 5 MET-limited submaximal exercise test
could be used before early discharge, with a follow-up
symptom-limited stress test at 3 to 8 weeks, A recent study
(196) that failed to show additional prognostic value gained
by the follow-up maximal stress test used a submaximal test
at 8 to 10 days . It suggested that a second symptom-limited
test at 6 to 8 weeks be reservedfor patients who develop new
symptoms or require functional capacity clearance for an
active life-style (1%).
Supplemental isagirrg (Table 2). Thallium-201 myocar-
dial perfusion scanning is frequently performed in associa-
tion with exercise testing in patients with conditions that
compromise interpretation of the ECG (bundle branch
block, rest ST-T wave abnormalities, digitalis therapy) . In a
study (197) of 140 patients after infarction, thallium-201
scintigraphy detected 94% of those who had a later cardiac
event and was more reliable than ECG changes on submax-
imal predischarge exercise testing in defining high and low
risk subgroups . Thallium-201 defects in multiple vascular
regions, redistnbuaon abnormalities or pulmonary uptake of
thaitium-20l identified more high risk patients than did ST
segment depression or angina (197). Recently, rest thallium-
201 imaging performed before discharge has been shown to
give prognostic information that, is one study (198), was a
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Table 2 .
Strategies for Predischarge or Early Postdischarge Exercise Evaluation
Clinical
Indicators of high risk at predtschuge
+ I
+	-
SymphaMinited Medical
exercsee .15-5 weeks treatment
+	
I I
Cardiac Medical
better predictor of outcome than either rest ejection fraction
by radionuclide ventriculography or 24 h Holler monitoring .
This technique can be considered for risk stratification in
patients after infarction who are judged to be unable to
perform exercise. Dipyridamole thallium-201 imaging has
also been advocated for the same exercise-restricted pa-
tients . At present, it remains a promising investigational
technique awaiting further confirmation (199) .
Radionuclide ventriculography measured at rest and dur-
ing exercise provides useful prognostic information . When
the rest ejection fraction is normal, a decrease in ejection
fraction during exercise correlates well with thallium perfu-
sion defects in the same patients (192) . Therefore, it is likely
that the exertional decrease in ejection fraction reflects myo-
cardial
ischemia (193). In one study (200), the predictive
accuracy of a failure to increase ejection fraction by 5 percent-
age units during submaximal exercise was 95% for any cardiac
event during a 10 month follow-up period . In another study
(195), exercise velnricscography during maximal symptom-
limited testing at 3 weeks correctly predicted >90% of episodes
of death, nonfatal ventricular fibrillation or reinfarction in the
subsequent year
. There has been no direct comparison of the
+
_1
Medical
trsetrmni
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predictive value of thallium-201 versus radionuclide ventricu-
logaphy when performed with a submaximal treadmill exer-
cise test before discharge (193)
. When the two techniques were
compared with maximal stress testing at 3 weeks, radionuclide
ventriculography was of superior prognostic value in patients
with a rest ejection fraction >40% (192) .
Wall motion abnormalities due to exercise-induced myo.
cardial ischemia can also be detected by two-dimensional
echocardiography either at peak bicycle exercise or, more
conveniently, immediately after treadmill exercise testing
(201). New or worsening wall motion abnormality on maxi-
mal stress testing soon after myocardial infarction (average
13 days) identified a high risk subgroup with greater sensi-
tivity and specificity than did echtlcardiographic abnormali-
ties alone (202) . Another study (203) reported similar prog-
nostic value of echocardiography when exercise was
submaximal with a heart rate limitation. Exercise echocar-
diography is a versatile and inexpensive imaging technique,
the validity of which is being established (204) .
In summary, the principle of predischarge or early post-
discharge exercise evaluation is based on first selecting cut
the patients who on clinical grounds are at high risk for
I I I
Cardiac StratagyI strategy it Strategy III
raeratarlaAlen
I I I
Symptom-Ilmsed Uncomplicated coon . muchness at
exercise at
10-14 days
+ sulxnaximal
exercise 7-14 days
with thallium
at 6.10 days
+ I -
+
- SYmplomd ndtsd
exercise
test with or
Ca dI c
Symptemtl mad
OWN.about .1
ealhrertratkn exercise at
3 weatw
4-wwekks
with d1111um
+ ~ -
Straouous telsere
f- I
Cardiac Medical
activity or occupation
easwtwlratbn mwlagamwn
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ischemic events and directing them to invasive evaluation .
Then the patients who have myocardium in jeopardy of
ischemic injury need to be identified with highest accuracy
and those who would undertake strenuous exertion be
provided a functional evaluation after partial or complete
rehabilitation.
One strategy is to perform a symptom-limited exercise
test, perhaps with thallium scanning or radionuclide ventric-
ulogrphy at 10 to 14 days . This could serve to determine
prognosis and identify most patients in the clinically low risk
group who have residual ischemia and therefore need inva-
sive evaluation. No additional exercise testing is needed in
those who do well on this early exercise test unless the
patient wants to undertake strenuous activity and needs a
test for functional evaluation after rehabilitation .
A second strategy is to perform a submaximal exercise
test at 6 to 10 days after the infarction and just before early
discharge
. This strategy requires very careful clinical assess-
ment to identify patients for early discharge, and there are
too few published data on early exercise testing to assess its
prognostic validity . For those patients identified as having
ischemia, it starts the process of invasive evaluation early,
whereas those who do well still need a symptom-limited
exercise test-perhaps with thallium-for prognosis and
function assessment at 4 to 8 weeks
.
A third strategy
is to discharge the clinically low risk
patient at 7 to 14 days and perform the symptom-limited
exercise, perhaps with thallium or radionuclide ventriculo-
graphic evaluation at 3 weeks for prognostic as well as
functional evaluation . This has the advantage of requiring
only one exercise evaluation, but has the disadvantage of
delaying invasive evaluation for 3 weeks in those patients
identified to have ischemia
. There is also a possibility of
postinfarction events occurring before this test .
If there is doubt about the exerciselthallium interpreta-
tion, exercise ventriculogrphy by radionuclide scanning or
echocardiography
can increase the sensitivity of the test by
identifying exercise-induced wall motion abnormalities .
Recommendations for Noninvasive Evaluation
of Patients at Low Risk by Clinical Indicators
Class I
I. Stress ECG
.
a) Before discharge for prognostic assessment (submax-
imal at 6 to 10 days or symptom-limited at 10 to 14
days).
b) Early after discharge for prognostic assessment and
functional capacity (3 weeks)
.
c) Late after discharge (3 to 8 weeks) for functional
capacity and prognosis if early stress was submaximal.
2. Exercise thallium-201 scintigraphy (whenever baseline
abnormalities of the ECG compromiGr its interpretation) .
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Class IIa
I . Exercise thallium-201 scintigrphy
; before discharge for
prognostic assessment with symptom-limited exercise at
10 to 14 days .
2. Dipytidamole thallium-201 scintigraphy (before discharge
for prognostic assessment in patients judged to be unable
to perform exercise) (pending expected Food and Drug
Administration approval) .
3. Exercise radionuclide ventriculogrphy predischarge at
10 to 14 days or early after discharge for prognostic
assessment .
4
. Exercise two-dimensional echocardiography (before dis-
charge or early after discharge for prognostic assessment)
.
Class fib
l . Stress ECG.
a) At any time to evaluate patients with a class 1 indica-
tion, but baseline ECG abnormalities or coexisting
medical problems that limit ability to achieve maximal
exertion. In sonic of these patients, exercise testing
may still yield clinically valuable information (duration
of exercise, blood pressure response, production of
chest discomfort, etc)
.
b) Before discharge or early after discharge to evaluate
patients who have sustained complicated myocardial
infarction, but who have subsequently "stabilized"
and for whom a decision for invasive evaluation has
not been made
.
2 . Exercise thallium-201 myocardial scintigraphy (late after
discharge at 6 to 8 weeks for prognostic assessment).
3
. Dipyridamole thallium or dobutamine thallium before
discharge in patients judged unable to exercise (not
approved by the Food and Drug Administration for this
indication),
Class III
1 . Stress ECG .
a) Within 72 h of acute myocardial infarction .
b) At any time to evaluate patients having unstable
postutfarction angina pectoris
.
c) At any time to evaluate patients with acute myocardial
infarction who have uncompensated congestive heart
failure, cardiac arrhythmia or noncardiae conditions
that severely limit their ability to exercise .
d) Before discharge to evaluate patients who have already
been selected for cardiac catheterization
. In this situa-
tion, an exercise test may be useful after cathetetizatim
to evaluate function or identify ischemia in distribution
of a coronary lesion of borderline severity .
Rest radtiauudide veatriculagriphy
. Guidelines for car-
diac radionuclide imaging have been previously published
(199) . The most widely available techniques include first
pass and equilibrium radionuclide ventriculography . Be-
muse ventricular dysfunction is a major predictor of infarc-
tion-related death, an accurate measurement of left centric-
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ular ejection fraction would be expected to aid in
postinfarction risk stratification. An assessment of ventricu-
lar function can be obtained by two-dimensional echocar-
diography at rest . At present, however, radionuclide ven-
triculogaphy is more commonly utilized. A progressive
increase in the t year mortality rate occurs as left ventricular
ejection fraction (measured by radionuclide ventriculogra-
phy) decreases <40% (174-176,178) . Some (205) have sug-
gested that a cutofflevel of45% is more sensitive and reveals
a high risk subgroup of more reasonable size . When radio-
nuclide ventriculography was performed late (I to 2 months
postinfarction), end-systolic volume was the best predictor
of survival over a 6 year follow-up period, being superior to
ejection fraction when ejection fraction was low (206).
Recommendations for Rest
Radionuclide Ventriculography
Clasn I
1 . Predischarge rest radionuclide ventriculography to deter-
mine the high risk subset unless determination of ventric-
ular function has been made by other means .
Class Ira
1
. For shunt detection in patients wits suspected ventricular
septat defect (pulmonary artery injection)
.
Class Ill
I . Prediseharge radionuclide ventriculography to detect left
ventricular thrombus .
2
. Where similar information can be derived from other tests
already performed or scheduled .
Two-dimensiunatcebocardiographyatresr. Guidelinesfor
the general use of echocardiography will be the subject of a
future ACC/AHA Subcommittee publication. In the setting
of acute myocardial infarction, two-dimensional echocar-
diography at rest has proved useful in the assessment of left
ventricular function and risk stratification. Estimates of left
ventricular systolic and diastolic volume and ejection frac-
tion can be obtained by several techniques . Left ventricular
function is more commonly and more usefully represented as
a semiquantitative "wall motion index," wherein a numeric
value representing hypokinesia, akinesia or dyskinesia is
visually assigned to wall segments (190)
. Predischarge two-
dimensional echocardiography at rest can identify patients at
higher risk of death, recurrent infarction or development of
congestive heart failure in the following 17 to 21 months
(202,207)
. More importantly, a normal wall motion index
early in infarction identifies a low risk subgroup that re-
mained free of complications with a negative predictive
accuracy of 95% (208) .
Unlike radionuclide ventriculography, two-dimensional
echocardiography detects wall thinning as well as abnormal
wall motion . Disproportionate infarction expansion and ven-
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tricular dilation can be detected and are associated with a
significant 2 month mortality rate (209). Furthermore, the
detection of asynergy remote from the area of infarction on
an echocardiogram identifies patients with multivessel dis .
ease and residual myocardium in jeopardy from ischentia
(210). Two-dimensional echocardiography can readily detect
the following complications of infarction : rapture of the
ventricular septum, papillary muscle or left ventricular free
wall, left ventricular aneurysm or pseudoaneurysm, mural
thrombus formation, infarct extension or expansion and
right ventricular infarction (211).
The advantages of two-dimensional echocardiography
include its portability and ease of performance. It can be
used in the coronary care unit on very sick patients and can
be repeated as necessary. It is painless and relatively inex-
pensive . Limitations include technical difficulties in obtain-
ing interpretable studies in some patients with unusual body
hubitus or overlying lung tissue obscuring the echocardio-
graphic window (211)
. In addition, wall motion scores,
though clearly predictive, have largely been of research
interest and clinicians have little direct experience in using
such indexes for day to day patient management decisions .
Recommendations for Two-Dimensional
Echocardiography at Rest
Class I
I . Detection or confirmation of suspected complications of
infarction: tissue rupture, aneurysm or pseudoaneurysm
formation, infarct extension or expansion, mural throm-
bus and right ventricular infarction .
Class; Ila
1 . For evaluation of left ventricular function in predicting a
low risk subgroup for ambulatory and early discharge
from the coronary care unit .
Class ltb
1 . Prediction of patients with multivessel coronary artery
disease by the detection of remote asynergy
.
Class IH
l . Where similar information has been obtained from other
tests already performed or scheduled.
Ambulatory continuous electtocardiogaphie monitoring
.
Guidelines for ambulatory electrocardiography have been
previously published (212). Twenty-four hour Holler moni-
toring before discharge detects less than one premature
ventricular complex per hour in >50% of patients after
infarction. These low risk patients have a 2
year mortality
rate of about 5% (60). The 15% to 25% of postinfarction
patients found to have ? 10 premature ventricular complexes
per hour on Holler monitoring have a 2 year mortality rate
>20% (174,177). Even as few as one to three premature
ventricular complexes per hour and certainly more than
three premature ventricular complexes or a single ventricu-
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tar premature couplet
in a 24 h recording markedly increases
the risk of death over s follow-up period of several years
(213,214). Increasing complexity of the ventricular arrhyth-
mia (pairs and runs of ventricular tachycardia) is associated
with decreasing survival (180,190,215) .
Although ventricular ectopic activity is strongly associ-
aled with left ventricular dysfunction, multiple regression
analysis in several large studies (175.180,212-215) has shown
it to be an independent risk factor for death after acute
myocardial infarction. Furthermore, although the risk of
death is greatest in patients with both complex ectopic
activity and left ventricular dysfunction, the risk ratio was
higher in patients with complex ectopic beats, even if they
were at low risk by all other criteria . In these clinically
uncomplicated patients, ectopic activity was infrequent, but
when present it quadrupled the risk of death (215) .
Electrophysiologic testing. This has also been utilized to
stratify patients with ventricular ectopic activity and coro-
nary artery disease . When programmed ventricular stimula-
tion induced sustained ventricular tachyarrhythmia
. the I
year mortality rate, even on antiarrhythmic therapy, ex-
ceeded 30% versus 2% for patients with noninducible ar-
rhythmias (216). Because there are no randomized trials
available to support the validity of this approach, however .
the application of electrophysiologic study to evaluate ven-
tricular ectopic activity occurring late after acute myocardial
infarction remains controversial
(48) . There is no indication
for the use of electrophysiologic study to evaluate ventricu-
lar tachycardia or cardiac arrest in the acute phase of
myocardial infarction (s48 h) (48) . Signal-averaged electro-
cardiographv is another promising technique that may prove
beneficial .. . defining a set.__, of patients at high risk for
sustained ventricular lachycardia (217) .
Whether antlarrhythmic therapy with enceinide, flecain-
ide or morieizine can be expected to improve the survival of
patients with significant ventricular arrhythmias is the sub-
jeer of a randomized multicenter study, the Cardiac Arrhyth-
mia Suppression Trial (CASTINHLBI) (219) . Preliminary
results from that trial reveal an increased incidence of
sudden death in patients treated with encainide or ikcainide
as compared with placebo-treated control subjects . All pa-
tients had demonstrated suppression of the ventricular at-
rhythmias before randomization to drug or placebo . Only
20%ef the patients had nonsustained ventricular tachycardia
and most had isolated premature ventricular beats . This
study shows that these class IC antiarrhythmic agents should
not be used in postmyocardial infarction patients with
aaymptomatic ventricular arrhythmias (218)
. The study does
not provide any evidence that suppression of such arrhyth-
mias has a positive therapeutic effect despite the evidence
that these arrhythmias define a group of patients at increased
risk of sudden death. There is no evidence that any drug .
with the possible exception of beta-blockers, alters the
incidence of sudden death.
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The Holler recording contains other information of
value
beyond documenting the frequency of premature ventricular
complexes. The Holier monitor can be programmed to com-
pute heart rue variability (standard deviation of all RR inter-
vats in sinus rhythm). In a large trial (219). heart rate variWity
had the strongest univariate correlation with mortality of all the
variables analyzed
(greater than any grade of premature ven-
tricular complexes, rales and left ventricular ejection fraction
<Wb) . This probably represents decreased vagal tale and
increased sympathetic activity during ischetnia, which would
tend to promote ventricular fibrillation. ST segment shifts
detected on calibrated continuous ambulatory ECO recording
after infarction seem to represent ischemia that is frequently
silent
. Such charges are associated with a significantly in-
creased I year mortality rate (220) .
Recommendations for 24 h Ambulatory
Continuous Flectrocardiography
Class Hs
1 . After myocardial infarction, patients with moderate to so-
vere left ventricular dysfunction for prognostic assessment .
2
. After myocardial infarction, patients with significant ven-
tricular ectopic activity in the coronary care unit or
stepdown telemetry unit for prognostic assessment .
Class Ilb
1 . After myocardial infarction . patients to determine heart
rate variability for prognostic assessment .
2_ High risk postmyocardial infarction patients as a screen
for silent ischemia.
Class III
I . Uncomplicated ambulatory patients after discharge as a
routine screen
.
Summary. As noted at the beginning of this section,
many of the described techniques are duplicative and the
clinician must choose the tests that are cost-effective, are
most accurate in his or
her environment and will lead to
clinical decisions that can modify outcome or at least make
a major impact on prognostication. One needs to decide if
cardiac catheterization is indicated during the initial hospi
.
talization or early convalescence and this frequently can be
done by clinical assessment and data collected early in the
initial hospitalization. Patients with an uncomplicated course
and not considered for early catheterization need evaluation
of tell ventricular function either by echocardiography or
radionuclide ventriculography and a search for evidence of
myocardium at risk for new infarction by use of one of the
three exercise strategies proposed
.
If there is electrical instability manifested by complex
ectopic beats or frequent ventricular premature beats during
the later course of the infarction, a 24 h ambulatory ECG
recording is indicated. If
there are runs of ventriculartachy-
296
	
GUNNAR ET AL.
ACCIAHA TASK FORCE REPORT
cardia, further electrophysiologic studies may be indicated,
but it must be realized that there are no large trials to support
the efficacy of antiarrhythmic therapy in the asymptomatic
group of such patients after myocardial infarction . Studies
showing efficacy of suppression of inducible sustained ven-
tricular tachycardia have all been done in patients with
chronic ischemic heart disease
.
There are those who recommend routine convalescent
cardiac catheterization and coronary angiography. This
would eliminate the need for much of the noninvasive testing
and eliminate exercise testing strategies in those selected
immediately for surgical or angioplasty intervention, Cost-
effectiveness is used as an argument, but we are not ready to
recommend such a routine course because outcome data are
not available as yet to support this aggressive strategy .
Coronary anglograpby. Guidelines for the utilization of
coronary angiography have been previously published (221) .
In essence, all of the risk stratification efforts described
using clinical assessment, exercise testing, radionuclide im-
aging, echocardiography and Holler monitoring have been
directed at defining a subset o : patients after infarction at
high risk for complications or premature death who would be
candidates for coronary angiography to determine the poten-
tial for revascularization . The prognosis in the first year after
infarction is directly related to the extent of coronary ob-
struction and the degree of left ventricular dysfunction
documented at angiography (176,222). The cost-effective-
ness of various management alternatives after uncompli-
cated myocardial infarction has been analyzed using a theo-
retic model (223). The most cost-effective strategy was that
which screened patients with treadmill exercise testing (with
thallium added where indicated) and recommended coronary
angiography and rvasctlarization in all but those patients
who had unequivocally negative studies .
Early Evolving Myocardial Infarction (initial
hours of myocardial infarction)
Class I
1
. All patients developing pump failure/shock syndrome .
2. All patients suspected of developing an acute ventricular
septal defect.
3
. Persistent or recurrent ischemia, or both, despite throm-
bolytic therapy.
Class Ha
I . When coronary angiography can be performed within the
first 6 h after the onset of chest pain in patients who are
candidates for revascularization therapy utilizing percu-
taneous transluminal coronary angioplasty or coronary
artery bypass surgery (but who are not candidates for
thrombolytic therapy).
2. Patients who have had a previous aortocoronary vein
graft if the graft is to the suspected infarct-related vessel
.
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Class fib
l. Patients who can be taken quickly for angioplasty or
bypass surgery in a facility set up and qualified for these
emergency procedures .
Class III
1. As a routine after early intravenous thrombolytic therapy .
2 . Patients with uncomplicated myocardial infarction having
no evidence of ongoing ischemic .
Late Evolving Myocardial Infarction (after
the initial 6 h up to but not including
predischarge evaluation)
Class I
1 . Patients with recurrent episodes of ischemic chest pain,
particularly if accompanied by ECG changes
.
2. Patients suspected of having acute mitral regurgitation or
a ruptured interventricutar septum causing heart failure
or shock.
3 . Patients suspected of developing subacute cardiac rup-
ture (pseudoaneurysm).
4
. Patients with cardiogenic shock or severe pump failure .
Class 112
1 . Patients will congestive heart failure during intensive
medical therapy.
2 . Patients with recurrent ventricular tachycardia or ventric-
ular fibrillation, or both, during intensive antiarrhythmic
therapy
.
Class Ilb
1 . Asymptomatic patients who have received thrombolytic
therapy during the evolving phase .
Class III
1 . Patients with uncomplicated completed myocardial infarc-
tion in whom no acute mechanical or surgical intervention
is contemplated .
Convalescent Myocardial Infarction (immediate
predischarge up to 8 weeks after discharge)
Class 1
I . Poslinfarction angina pectoris .
2. Patients with evidence of myocardial ischemia on labora-
tory testing: exercise-induced ischemic (with or without
exercise-induced angina pectoris), manifested by a I mm
of ST segment depression or exercise-induced reversible
thallium perfusion defect or defects, increased lung thal-
lium
uptake or exercise-induced reduction of the ejection
fraction or wall motion abnormalities on radionuclide
ventriculography or two-dimensional echocardiography .
Class Ila
l . Patients with tl:e need to return to unusually active and
vigorous physical employment.
2 . Patients with a left ventricular ejection fraction <40%.
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Class lib
1 . As a routine in patients receiving thrombolytic therapy
during the evolving phase of infarction .
2.
Otherwise uncomplicated and asymptomatic patients
who are <45 years of age.
3 . Patients with uncomplicated non-Q wave myocardial
infarction not otherwise manifesting evidence of myocar-
dial ischemia on noninvasive laboratory testing.
Class IH
1 . Patients judged to have a debilitating disease or condi-
tions that preclude their being candidates for invasive
intervention.
2. Patients with coexisting disease judged to be primarily
responsible for the patients' prognosis, with a greatly
shortened life expectancy unless revascularization is de-
termined to be necessary to facilitate treatment of the
underlying disease .
3 . Patients with very advanced left ventricular dysfunction
(ejection fraction <20%p) in the absence of angina pectoris
or evidence of ischemia. An exception is the patient who
is a candidate for aneurysmectomy or cardiac
transplan-
tation.
4. Patients with ventricular arrhythmias who have no evi-
dence of ischemia symptomatically or during exercise
testing, well preserved exercise tolerance and no sugges-
tion of aneurysm formation . An exception may be the
patient with inducible sustained ventricular tachycardia .
Follow-up care. The Subcommittee decided to not in-
clude any detail regarding modification of coronary artery
disease risk factors in this report . We believe strongly that
this is a major task for the clinician discharging and following
up the patient after monitoring his or her infarction . but
because of space limitations we have left this task to other
reports. We urge clinicians to become involved in treatment
of lipid abnormalities, stopping smoking, treating hyperten-
sion, weight control, exercise, prescriptions and seeing that
this
modification is a life-style change rather than just a
temporary change induced by the fright of the acute episode.
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ischemic agents effective in the treatment of stable and
unstable angina pectoris resulting mum fixed steaoses of
coronary atherosclerosis and from coronary vasospasm . The
known cardiovascular properties of these drugs suggest a
rationale for their use in the treatment of acute myocardial
infarction and in the prevention of secondary complications
after myocardial infarction . Although some new calcium
channel blocking drugs are under investigation, this discus-
Am will be limited to those now in clinical use-verapamil,
nifedipine and diltiazem. All three reduce systemic vascular
resistance and, therefore, are utilized as antihypetsenaive
agents (83)
.
They have been shown to influence the ionic
calcium currents that regulate action potential (84) . Dih-
iazem and verapamil both reduce myocardial contractility,
thereby diminishing myocardial oxygen consumption, as
dices nifedipine if reflex sympathetic stimulation is blocked
(85).
Diltimm and verapamil have potent effects on the AV
node, producing slowing of the ventricular response to atrial
flutter and fibrillation, terminating paroxysmal supraventric-
ular arrhythmias and occasionally producing AV block .
Despite these multiple cardiovascular effects of the cal-
cium channel blockers, there have been only a few reports
(86,87) evaluating their use in acute myocardial infarction .
Dgtiazem. The Diltiazem Reinfaretion Study Group (88)
reported that in the dose of 90 mg every 6 h, initiated within
24 to 72 h after onset of infarction, dittiazem was effective in
preventingearly reinfarction and recurrent angina in patients
with non.Q wave infarction (formerly designated Contrans-
mural or subendocardial infarction)
. The study of long-term
di[tiazem therapy in patients with both Q wave and non-Q
wave myocardial infarction failed to demonstrate abeneficial
effect of diltiazem . Although there were slightly fewer recur-
rent cardiac events overall in the diltiazem group as opposed
to the placebo group, this did nor reach statistical
signifi-
cance. in patients receiving dibiazem, there appeared to be
to adverse effect in the small group of patients with left
ventricular dysfunction and this may have obscured the
favorable effects in patients with normal ventricular fanc-
lion, but this was not tested prospectively, Thus, the efficacy
of routine diltiazem treatment after acute myocardial infarc-
tion in patients with preservation of left ventricular function
is not yet established,
Vaapam8. This agent may
be beneficial in the setting of
acute myocardial infarction for the treatment of acute su-
praventricular arrhythmias, particularly ifather antiatrhythmic
drugs (suck as digoxin) are inadvisable and neither ventricular
function nor the conduction system is in jeopardy . Care should
be exercised in patients receiving beta-blockers
.
Needipine . Muller et al. (89) reported the results of& trial
to determine whether early nifedipine therapy could prevent
progression or extension of infarction as determined by MB
CK values and whether nifedipine would limit necrosis in
patients with ongoing acute myocardial infarction with a
primary end point being the serum enzyme determination of
JACC Vat. 16, No.
2
AUS0211990219A2
infarct size (89). The results showed no reduction in the
progression to infarction or a reduction of infarct size, but
the nifedipine group bad a significantly higher 2 week mor-
tality rate than the placebo group (p < 0 .02) .
Thus, therein no clear evidence to support the routine use
of calcium channel blockers in the treatment of acute myo-
cardial infarction (90),
except in the subset of patients with
nomQ
wave
infarction, in whom diltiazem was found effect
Live in preventing early reinfarction and recurrent severe
angina .
Recommendations for Use of Calcium Channel
Rlockers in Acute Myocardial Infarction
Class f
1 . Symptomatic treatment of postinfarction angina while
awaiting cardiac catheterization and therapy based on
angiographic findings.
Class 11w
1 . Diltiazem in patients with non-Q wave infarction in whom
no contraindication exists, It should be started during the
first 48 h and continued through the hospital phase and
the first postinlarction year.
2. After angioptasty, a calcium channel blocker to preyed
coronary vascapasm .
Clms 136
1 . A calcium channel blocker may be used in transmaeal (Q
wave) infarction for treatment of postinfaretion angina,
especially if contraindications to proceeding with coro-
nary arteriography and more definitive treatment exist .
Case m
1 . Calcium channel blockers that suppress ventricular func
.
Lion inpatients with myocardial infarciion complicated by
pulmonary congestion or left ventricular dysfunction.
Thrombolyfie
Therapy in Patients With
Acute Myocardial Warction
Background, Approximately 66% of heart attack victims
at hospital entry have ST segment elevation, making it Rely
That the process is caused by an occlusive coronary clot . In
patients with this finding, clot-dissolving therapy in the farm
of intravenous streptokinase (SK [StreptasclKabikinasel),
recombinant tissue-type plasminogen activator (re-PA (Acti-
vasel) -or anisnylated plasminogen streptokinase activator
complex (APSAC lAnistreplascl) can dissolve the clot and
restore flow, interrupt the infarction, reduce myocardial
necrosis and improve survival if therapy is delivered within
6 h of the onset of the attack
.
Results of dlnteul Mars, The use of thrombolytic therapy
in acute myocardial infarction with ST segment elevation
rests on reductions in mortality observed in randomized
controlled trials (Table 1).
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